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1 INTRODUCTION 
 
1.1 Nucleic acid based therapy 
The idea of nucleic acid based therapy is an exciting, rational notion, tackling many 
serious diseases at the root of their origin, at gene level. Classic gene therapy utilizes 
DNA, preferentially delivered by viral vectors, to insert functional genes into the 
human genome for replacement of defective gene sections. This way, genetic 
disorders like severe combined immunodeficiency (SCID) [1], mucoviscidosis [2] or 
haemophilia [3], as well as acquired diseases like viral infections [4, 5] have been 
addressed. DNA based therapy has been extended to other fields like DNA 
vaccination [6], cancer therapy [7] and many more. Although remarkable success has 
been achieved, e.g. in treatment of SCID, considerable side effects have been 
reported and safety concerns about interference with the human genome remain. 
In recent years, focus of nucleic acid research shifted to the exploitation of RNA for 
therapeutic purposes. Since the discovery of RNA interference (RNAi) by Fire et al. in 
1998, significant efforts and resources have been invested in exploiting the 
therapeutic potential of RNA for the treatment of human diseases [8-11]. The RNAi 
process makes use of double stranded RNA for specific gene silencing [12, 13]. The 
introduction of exogenous long dsRNA (>30 nucleotides) into cells was found to 
inhibit cellular protein expression, provoke innate immune response by interferon 
activation, and induce apoptosis. A boost of attention for RNAi followed when Tuschl 
et al. demonstrated that gene target-specific RNA interference without significant side 
effects can be mediated by application of small synthetic 21-23 nucleotide interfering 
RNA (siRNA) duplexes [14]. As siRNAs reach the cytosol of cells, they are loaded 
onto a multiprotein complex called RNA induced silencing complex (RISC) (Figure 1). 
After incorporation into RISC the siRNA is unwound by the enzyme Argonaute 2 and 
the sense strand is cleaved [15, 16]. The antisense strand (‘guide strand’) remains 
incorporated and activates RISC to cleave complementary mRNA [17]. Because an 
activated RISC is capable of repeatedly cleaving mRNA, this process effectively 
promotes gene silencing over a significant period of several days. Therefore, siRNA 
has become an indispensable tool for studying gene function in mammalian cells and 
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the sequence-specific interaction on mRNA level holds great promise for a vast 
variety of gene-specific therapeutics. 
 
 
Figure 1: Mechanism of RNA interference (RNAi). After reaching the cytosol, siRNA is loaded into the 
RNA induced silencing complex (RISC), a multi enzyme complex. After unwinding of the double 
strand, the sense strand is degraded and the antisense strand (‘guide strand’) is loaded to the core 
protein Argonaute 2 (Ago2). Base pairing between the guide strand and a complementary target 
mRNA leads to cleavage of the mRNA strand by the activated RISC. R2D2: double-stranded RNA 
binding protein. Figure modified from Li et al. [18]. 
 
Besides siRNA, there are other types of therapeutic RNAs, including target-binding 
RNA aptamers [19], antisense RNAs, or immunostimulatory RNAs (Figure 2). The 
delivery of antisense RNA (single stranded RNA) presents the most straightforward 
way to inhibit gene expression. Antisense RNA oligonucleotides like siRNA interfere 
with gene expression by binding to their complementary mRNA strands [20]. Usually 
one antisense RNA can inhibit only one mRNA molecule and therefore is less 
effective than catalytically active siRNA. Novel interesting options of exploiting the 
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antisense mechanism are exon-skipping [21] or the targeting of micro RNAs with 
complementary oligoribonucleotides (anti-miRs) [22]. 
 
 
Figure 2: Cellular entry of RNA polyplexes and intracellular mechanisms of different therapeutic RNAs 
(double stranded as shown in figure or single stranded). The different types of RNA execute their 
biological function inside the cell. siRNA is loaded onto RISC for cleavage of corresponding target 
mRNA, in this way knocking down gene function. Poly-IC or 5’-triphosphate-modified RNA initiate 
distinct immune responses, whereas single stranded oligonucleotides may modulate gene functions 
by antisense mechanisms, including microRNA targeting or exon-skipping. 
 
MicroRNAs regulate the expression of genes by interfering with protein translation, 
and the silencing of a specific microRNA by the delivery of anti-miR consequently 
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leads to an altered expression of the corresponding gene. Other interesting 
approaches apply immunostimulatory and cytotoxic RNAs. Poly-IC (poly-Inosine-
Cytosine), a synthetic double stranded RNA, mimics the expression of dsRNA in 
virus-infected cells, which via endosomal toll-like receptor TLR3 and cytosolic mda-5 
stimulation activates different pro-apoptotic processes simultaneously. This makes it 
an interesting tool for cancer treatment because the induced mechanisms lead to cell 
death and the additional expression of anti-proliferative cytokines like interferons 
inhibits growth of neighbouring cancer cells that have not been “infected” with poly-IC 
[23, 24]. Other immunostimulatory RNAs contain 5'-triphosphate ends, which activate 
innate immune cells and lead to direct interferon expression and apoptosis in tumor 
cells via recognition by the antiviral helicase Rig-I. Hartmann et al. used a 
combination of gene silencing and immunostimulation. Administration of siRNA, 
targeted against Bcl-2 and containing immunostimulatory 5'-triphosphate ends, 
provoked strong tumoral apoptosis in a lung metastasis model [25]. The same group 
recently showed that activation of Rig-I and Mda-5 helicases by RNAs with 5'-
triphosphate ends also initiates an interferon independent signalling pathway in tumor 
cells, resulting in apoptosis [26]. Due to the dual pathway of inducing apoptosis, this 
may be an effective strategy of facing the frequently occurring drug resistance 
problems in many tumors. 
Although therapeutic RNAs have the potential to revolutionize medicine, so far naked 
RNA formulations have only been administered successfully to local tissues by direct 
injection, e.g. into the eye for the treatment of adult late stage wet macular 
degeneration (AMD) [27]. Barriers for systemic application of RNA are the relatively 
large size (siRNA: ~13 kDa), the negative charge due to the phosphate backbone, 
both hindering crossing of cellular membranes, and their susceptibility to enzymatic 
degradation in the bloodstream. However, a break through of this technology in the 
clinic requires easy-to-handle systemic applications to address a broad range of 
disease indications. For this purpose, safe additional carrier systems have to be 
developed, which are able to protect RNA in the extracellular environment and 
effectively deliver it to the site of interest. Viral and non-viral delivery strategies are 
being pursued. Viral delivery of RNA is very effective but there are also significant 
disadvantages like high production costs, immune response and safety concerns. 
Among the non-viral delivery systems peptides, RNA-conjugates [28, 29], cationic 
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polymers [30-36], lipids [37, 38] and lipid-modified polymer formulations [39-42] are 
explored. 
 
1.2 Optimization of the RNA payload 
Besides development of appropriate carriers for efficient siRNA delivery, both 
potency and specificity of siRNA can be enhanced by chemical modifications [43]. 
Unmodified siRNAs are unstable in blood because of rapid degradation by serum 
nucleases. They have been found to unspecifically activate the immune system to 
varying extent [44, 45] and they may trigger sequence-dependent off-target effects by 
partial sequence complementarity in the seed region, resulting in micro RNA-type 
inhibition of protein translation [46]. Chemical modifications of the 2`-OH group in the 
ribose residues, including 2`-O-methyl [47] and 2`-fluoro [48] modifications, stabilize 
against endonuclease, phosphorothioate linkages at the 3’-end against exonuclease 
activity. Furthermore, the incorporation of locked nucleic acid (LNA) nucleotides, in 
which the ribose moiety is modified with an extra bridge connecting the 2' and 4' 
carbons, increases thermal stability of the siRNA base pairing without negative 
effects on RNAi efficiency [49]. Besides resistance to digestion by nucleases, specific 
2`-O-methylation of the seed region (nucleotides 2 – 8 of the guide strand), the main 
interaction site with mRNA in RISC, was also shown to eliminate off-target effects, 
like activation of the immune system [50, 51]. Recently, Bramsen et al. [52] screened 
a large number of chemically modified siRNAs to generate design rules for high 
stability, high activity and low toxicity. Comparing the effects of 21 types of chemical 
modifications and screening 2160 siRNA duplexes they found that siRNA activity can 
be enhanced by favoured incorporation of the antisense strand (guide strand) into 
RISC. This can be triggered by chemical modifications which create a 
thermodynamic asymmetry of the siRNA duplex and engineering the 3’-overhangs 
[52]. The strand with the thermodynamically less stable 5’-end is preferred as guide 
strand in RISC. 
The classical 21 bp double stranded siRNA molecules are not the only possible 
trigger for RISC induced gene silencing. Other RNA forms have also shown effective 
gene knockdown [18], for example dicer substrate siRNA (dsiRNA), asymmetric 
interfering RNA (aiRNA) or small internally segmented interfering RNA (sisiRNA). 
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dsiRNAs, 25 – 30 bp RNA duplexes, are substrates of the cytosolic Dicer 
endonuclease, which processes the dsiRNA into siRNA. By using the natural 
processing machinery some dsiRNAs are more potent than the corresponding 
conventional siRNAs [53].  aiRNA [54] consists of a short, 14 – 15 nucleotide sense 
strand, paired to the middle segment of a conventional 21 nucleotide guide strand. 
The asymmetric duplexes combine effective and durable gene silencing with reduced 
off-target effects by the shortened sense strand. sisiRNA [55] is composed of three 
RNA strands: two short 10 – 12 nucleotide sense strands, complementing one intact 
antisense strand (guide strand). The lack of an intact sense strand reduces potential 
off-target effects. 
 
1.3 Non viral carrier systems for siRNA delivery 
The most prominent non viral delivery systems for siRNA that are currently explored 
rely on the formation of nanoparticles. These systems are mostly built up of lipids or 
polymers [56-59], which package the negatively charged nucleic acids into particles 
of nano scale dimensions, protecting them from degradation and delivering them to 
the cytosol of target cells. 
Representatives for lipid based siRNA formulations are liposomes and lipoplexes. 
Liposomes encapsulate siRNA into a lipid bilayer, formed by cationic lipids like 
DOTAP, DOPE, DSPC etc., representing amphiphilic molecules with a hydrophobic 
tail and cationic, hydrophilic head group. Internalized liposomes are able to 
destabilize the endosomal membrane by lipidic interaction and thereby release their 
payload into the cytosol [60]. Liposomal siRNA formulations are probably the most 
studied siRNA carriers in vivo [38, 61]. Within this class of carriers the formulation of 
Stable Nucleic Acid Lipid Particles (SNALPs), based on a mixture of cationic lipids, 
cholesterol and PEG lipids received special attention and demonstrated promising in 
vivo results [37, 62]. Lipoplexes represent an alternative approach of utilizing cationic 
lipids for siRNA delivery in vivo. They are produced by mixing a preformed cationic 
liposome with siRNA, resulting in a complex, where nucleic acid is incorporated at 
the outside shell of the liposome [63]. Systemic application of lipoplex formulations 
inhibited tumor progression in orthotopic cancer models [64, 65]. Major drawback of 
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lipidic systems is their preferential accumulation in the liver, often limiting their use to 
hepatic applications. 
Cationic polymers are able to bind nucleic acids through their positive charge by ionic 
interaction with the negatively charged phosphate groups of the nucleic acids and 
have the capability to form nanoparticles with these by complexation [66]. The so 
called polyplexes are generated simply by mixing the RNA with polymer.  
The widely used “golden standard” for gene transfection, polyethylenimine (PEI), has 
also been explored for RNA delivery. One of the reasons for PEI`s effectiveness is 
that it binds and protects the nucleic acid cargo against degradation, and promotes 
endosomal escape, a crucial step in the delivery process (Figure 2), through the 
“proton-sponge effect” [67]. Once the polyplexes have entered the cell via 
endocytosis, the acidification of the endosome enhances the positive charge density 
of the polymer. This leads to an enhanced influx of chloride and water, swelling of the 
endosomes which due to the cationic polymer interaction finally burst and release the 
payload into the cytosol. Whereas for gene delivery both linear PEI and its branched 
relative brPEI show high pDNA transfection results, the efficiency of PEI for siRNA 
delivery is less clear. Screening different PEI structures, Grayson et al. could only 
show in vitro gene silencing efficiency for brPEI formulations and here only within a 
narrow window of conditions [68]. Aigner et al. on the other hand successfully 
demonstrated in vivo gene silencing with linear polyethylenimine/siRNA formulations 
in several tumor models [69, 70]. Furthermore, local administration of linear 
PEI/siRNA to the lung resulted in strong gene knockdown [71]. By modifying siRNA 
with sticky overhangs to further stabilize the PEI polyplexes, systemic delivery to the 
lung was possible [72]. However, the major drawback of these simple and effective 
polymers is cytotoxicity. In addition, PEI is not biodegradable.  
One way to cut back cytotoxicity is to create derivatives of PEI through introduction of 
negatively charged propionic acid or succinic acid groups and other modifications of 
the amines, as reported by Zintchenko et al [73]. These derivatives showed far lower 
cytotoxicity compared to unmodified PEI and a high efficiency in siRNA-mediated 
knockdown, especially the succinylated branched PEI. 
Akinc et al. created a whole library of lipid-modified cationic oligomers (lipidoids). 
Screening of over 1.200 lipidoids, varying in alkyl chain length, linkage between alkyl 
and amines, different residues on the amines, identified lead structures for siRNA 
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delivery in cell culture experiments. Optimization yielded formulations for successful 
functional delivery of siRNA or 2’-methoxy RNA in vivo in several animal models [74]. 
Polycationic dendrimers like polyamidoamines (PAMAMs) are characterized by a 
branched spherical shape and high density surface charge. The primary amine 
groups on the surface of PAMAM enable RNA binding, while the tertiary amino 
groups inside the dendrimer are supposed to act as a proton sponge in endosomes 
and enhance the release into the cytoplasm [75]. Functionality of the polymers was 
recently demonstrated by siRNA-induced silencing of cancer relevant heat-shock 
protein 27 in prostate cancer cells, leading to apoptosis in vitro [76]. In order to 
reduce the cytotoxicity without losing gene silencing efficiency, surface- and core-
modifications have been introduced to PAMAM dendrimers [77]. 
Apart from synthetic polymers, various biopolymers like atelocollagen [78, 79] and 
chitosan have been exploited for gene silencing. Chitosan, a linear polysaccharide 
composed of randomly distributed β-(1-4)-linked D-glucosamine and N-acetyl-D-
glucosamine, has several beneficial qualities for in vivo use: low toxicity, low 
immunogenicity and biodegradability. Its high positive charge enables the biopolymer 
to bind RNA and form nanoparticles with it. Effective in vitro siRNA delivery using 
chitosan/siRNA nanoparticles was shown by several groups [80, 81]. In vivo efficacy 
of chitosan was demonstrated by Howard et al, amongst others, by systemic 
administration of chitosan/siRNA nanoparticles, in a murine arthritis model [82]. 
 
1.4 Functional domains of polymeric carriers facilitating nucleic 
acid delivery 
1.4.1 Shielding agents 
For successful in vivo delivery, polyplexes have often been functionalized with 
hydrophilic molecules like polyethylene glycol (PEG), resulting in a prolonged 
circulation time of the polyplexes in the bloodstream, reduced susceptibility to 
aggregation with serum proteins and reduced degradation via phagocytosis by cells 
of the reticulo-endothelial-system (RES). Different PEGylation strategies have proven 
successful, e.g. incorporating PEG into the polymeric carrier system [83], direct 
PEGylation of RNA before complexation [84, 85] or PEGylation of the polyplexes 
after complex formation (post PEGylation) [86]. Rädler et al. created diblock 
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copolymers consisting of PEG and cationic peptide for the formation of shielded 
siRNA complexes, containing only one single siRNA. The same work addressed the 
important issue of a reduced endosomal release due to the PEG coat. In one of the 
block copolymers, PEG was attached to the polymeric carrier via a pH-sensitive 
hydrazone linkage. This linkage is cleaved in the acidic environment of endosomes, 
in consequence the PEG shield is stripped off and endosomal release efficiency is 
restored [87]. The disadvantage of shielding polyplexes with PEG is that the positive 
surface charge of polyplexes is diminished, which is an important factor for cell 
adhesion and in consequence cellular uptake (Figure 2). However, this loss of 
efficiency, which besides would promote undesirable unspecific uptake into various 
cells in vivo, can at least be partly compensated by introducing targeting ligands into 
the polyplexes. Another versatile method to escape the PEG dilemma is the 
alternative use of biodegradable hydroxyethyl starch (HES) for shielding. The HES 
shield of polyplexes is slowly enzymatically degraded during blood circulation and 
thus leads to gradual deshielding of polyplexes, facilitating enhanced cellular 
internalization [88]. 
 
1.4.2 Ligands for cellular targeting 
Specific tissue targeting is essential for effective in vivo nucleic acid delivery at low 
doses that would not trigger side effects at other sites. The long lasting experience in 
the field of targeted gene delivery of liposomes or nanoparticles serves as a basis in 
the development of effective RNA delivery agents. Various ligands have been 
incorporated into the carrier systems that are specifically recognized by receptors 
expressed on cell surfaces. Once the ligand has bound to its corresponding receptor, 
the carrier system and its payload may be taken up by the cell via receptor-mediated 
or related forms of endocytosis. Several ligands have shown to be suitable for 
targeted gene delivery, e.g. anti-receptor antibodies, fragments of antibodies, 
peptides, aptamers, glycoproteins etc. [89-92] and several of them have already 
been screened for use in RNA delivery.  
For example, integrins have been studied as receptors for siRNA delivery at an early 
stage. They are expressed on the activated endothelial cells in tumor vasculature 
and it is known that the arginine-glycine-aspartic acid (RGD) motif of fibronectin is 
responsible for the ligand-receptor interaction [93]. Schiffelers et al. attached the 
Introduction                                                                                            
 
 
13 
RGD motif to the end of a PEG-conjugated polyethylenimine and used the modified 
polymer for selective tumoral delivery of siRNA to tumor-bearing mice [33]. 
Wang et al. [94] selected the most effective polymer (EHCO) of their library and 
functionalized it with bombesin peptide analogue, which exhibits high binding affinity 
to bombesin (BN) receptors. BN receptors are over-expressed on the cell surface of 
various cancer cells and therefore ideal for targeting strategies in cancer therapy [94, 
95]. 
The transferrin (Tf) receptor, a cell surface receptor for the uptake of the glycoprotein 
Tf, is also over-expressed in many types of tumor cells because of their fast growth 
and therefore high demand for iron, which is carried by Tf. Several research groups 
have utilized the Tf receptor for targeting their RNA vehicles [96-98].  Davis and 
colleagues [98, 99] studied the impact of incorporating Tf into a cyclodextrin-
containing polycation/siRNA formulation on delivery efficiency in tumor bearing mice. 
The epidermal growth factor (EGF) has caught much attention as a possible target 
ligand because the EGF receptor is strongly expressed on many types of cancers. 
Apart from the advantage of a specific receptor-mediated uptake, EGF also greatly 
accelerates intracellular uptake of the polyplexes [100]. Synthetic double stranded 
RNA (polyinosine-cytosine), a potent activator of apoptosis and interferon response, 
was selectively delivered to cancer cells by an EGF targeted PEI-PEG conjugate 
[23]. 
Instead of incorporating the targeting moiety into the polymeric carrier, it is also 
possible to couple it directly to the nucleic acid. For example, a luteinizing-hormone 
releasing hormone (LHRH) peptide analogue was covalently attached to siRNA 
against VEGF via a PEG spacer. The siRNA-PEG-LHRH conjugate formed 
nanosized polyelectrolyte complex (PEC) micelles upon mixing with PEI and 
achieved enhanced VEGF gene silencing on LHRH receptor over-expressing ovarian 
cancer cells compared to polyplexes without LHRH [101]. 
 
1.4.3 Intracellular release functions 
The major bottleneck for polymer based RNA formulations is the effective release of 
the payload from the endosome into the cytosol. Ways of overcoming this problem 
are for example making use of the proton sponge effect of some polycations or the 
incorporation of lytic lipid moieties into the polymer. Another versatile method is the 
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coupling of endosomolytic peptides to the carrier system. Lytic artificial peptide 
sequences or natural sequences derived from influenza virus haemagglutinin HA2, 
HIV gp41 envelope glycoprotein, melittin and others have been applied [102-109].  
For example, Pun and colleagues covalently linked PEI with the HIV gp41-derived 
fusion peptide [107]. This effectively increased endosomal release and the gene 
silencing activity of siRNA polyplexes. 
 
1.4.4 Dynamic functionalized RNA carriers 
The described different delivery functions are required at different time points of the 
delivery process. In fact, some of the steps request radical changes in the carrier 
characteristics. For example, polymers should strongly bind and protect the RNA in 
the blood circulation, but efficiently release it in the cytosol. PEGylation should shield 
polymeric carriers against unspecific interactions with proteins and cell membranes in 
blood, yet after specific cellular uptake the same carrier should interact with the 
endosomal lipid membrane and destabilize it. Therefore RNA carriers have to be 
dynamic in their characteristics, like natural viruses, to be most effective at the 
different steps of extracellular and intracellular delivery [110-112]. The requested 
changes can be programmed into the carriers by introduction of bioresponsive 
cleavable bonds or conformations. The acidification in the endosome [113-117] or 
cleavage of disulfides in the cytosol [109, 118] may trigger the changes. Figure 3 
shows two published examples illustrating the concept [31, 119]. In both examples 
siRNA was covalently coupled to the carrier polymer by bioreducible disulfide bonds. 
Thereby the risk of fast polyplex dissociation in the extracellular environment is 
eliminated. Meyer et al. [119] applied polylysine (PLL) as carrier, functionalized with 
PEG and a pH-responsive form of the lytic peptide melittin. At physiological pH the 
amines of melittin were masked with dimethylmaleic anhydride, which minimizes lytic 
activity. After endosomal acidification the protecting groups are cleaved and lytic 
activity is restored. This modification greatly enhanced gene silencing efficiency in 
vitro. Rozema et al. [31] used a different type of polymeric carrier, containing 
membrane-active modified vinyl ether subunits, reversibly shielded by PEG residues 
which are removed in a pH-sensitive fashion in the endosome.  The “Dynamic Poly 
Conjugates” are able to deliver covalently attached siRNA to hepatocytes both in 
vitro and in vivo after i.v. injection. 
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Figure 3: Bioresponsive siRNA-polymer conjugates. (A) Endosomolytic siRNA-poly-L-lysine 
conjugate (K represents L-lysine monomer, PEG polyethylene glycol) [119]. Cleavage of the 
dimethylmaleic anhydride (DMMAn) masking groups after endosomal acidification restores the lytic 
activity of melittin (Mel) and promotes endosomal escape; in a final step siRNA is released from the 
conjugate after disulfide cleavage in the reducing cytosol. (B) Dynamic PolyConjugate for hepatocyte-
targeted delivery [31]. Endosomal acidification triggers cleavage of the shielding agent (PEG) and 
targeting ligand (NAG, N-acetyl galactosamine) and activates endosomolytic properties of the polymer 
backbone; subsequently the siRNA is released by cleavage of the disulfide bond. 
 
1.5 Solid phase assisted synthesis for rational polymer design 
A major drawback for most established polymeric carriers is their polydispersity, due 
to the applied synthesis strategies. This limits structure/efficiency correlations and 
batch reproducibility, especially when polymeric structures become more complex, 
e.g. by incorporation of functional domains. Solid phase synthesis of polymers 
presents an interesting alternative, leading towards precise, sequence-defined 
polymeric carriers. Solid phase peptide synthesis (SPPS), introduced by Merrifield in 
1963 [120], allows the controlled step-by-step attachment of natural amino acids, as 
well as artificial amino acids with modifications suitable for nucleic acid binding. Solid 
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beads (resin), functionalized with linker units, form the anchor and starting point for 
multiple peptide coupling steps (Figure 4). 
 
 
Figure 4: Solid phase peptide synthesis for assembly of defined, monodisperse polycations, suitable 
for nucleic acid delivery. Defined cationic building blocks are coupled to the solid phase in multiple 
rounds and the final structure is subsequently cleaved from the resin, yielding sequence defined 
polycationic carriers. 
 
After completion of the peptide sequence, the construct is cleaved from the resin, for 
example by treatment with trifluoracetic acid. Because the peptide is immobilized on 
the solid phase during synthesis, until it is cleaved from the resin after the last 
reaction step, it can be purified by filtration after each coupling step. High coupling 
efficiency during each synthesis step is ensured by treatment of the growing peptide 
chain with a major excess of the next amino acid. Combination of high coupling 
efficiency with purification from reagents and by-products after each coupling step 
yields pure and highly defined structures. Additionally, this synthesis method allows 
the incorporation of functional moieties like shielding domains or targeting ligands at 
defined positions within the structure. Hartmann and colleagues transferred this 
method to the assembly of nucleic acid carriers, rendering sequence defined 
polyamidoamines [121, 122]. 
Based on standard peptide synthesis, Leng et al. generated various branched 
carriers consisting of lysine and histidine residues (with different degrees of 
branching, length of terminal arms, and changed histidine–lysine sequences) and 
identified suitable carriers for siRNA delivery with minimal toxicity and knockdown 
activity in vitro and in vivo [123, 124]. 
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Wang et al designed a small library of novel multifunctional siRNA carriers, reversibly 
polymerizable surfactants with pH-sensitive amphiphilicity, using combinatorial solid-
phase chemistry [40]. The polymerizable surfactants are made up of two lipophilic 
tails, a protonatable amino head group for siRNA complexation and two cysteine 
residues, enabling the construct to encage siRNA by autoxidative polymerization of 
the dithiols. 
 
1.6 Aims of the thesis 
Nucleic acid based therapy holds great promise for the treatment of multiple serious 
diseases at the root of their origin. Especially the exploitation of RNAi by the use of 
siRNA seems a safe and direct way for therapeutic application of nucleic acids in 
humans. However, for similar success as other biological therapeutics like peptides 
and proteins, which are extensively used in extracellular pathways, nucleic acid 
therapeutics require intracellular delivery to be active. The current lack of efficient 
delivery systems for siRNA hampers its broad application in the clinic. Focus of the 
current thesis was laid on the exploration and characterization of novel polymeric 
siRNA delivery systems with high efficiency and good biocompatibility. Within this 
work, the systematic evaluation of structure-activity relationships received special 
attention, as this yields important conclusions for the optimization of siRNA carriers. 
The first aim of the thesis was to physically stabilize labile siRNA polyplexes, based 
on a pseudodendritic, biodegradable polymer, which lacked gene silencing efficiency, 
for optimization of siRNA delivery. This should be achieved by crosslinking the 
surface of the in situ formed polyplexes with an amine reactive crosslinking agent, 
forming a cage around the particles. Biodegradability of the polyplexes should be 
maintained after chemical modification for a low toxicity profile of the siRNA 
nanoparticles. The optimum relation between polymer, siRNA and crosslinking agent 
should be determined for maximum delivery performance. Biophysical and biological 
properties of such stabilized particles should be examined for their potential as an 
effective siRNA delivery system. 
The second aim of the thesis was the evaluation of a small library of novel, sequence 
defined oligomers, based on new oligo (ethane amino) amides and solid phase 
assisted peptide synthesis, for their efficiency as siRNA carriers. The defined 
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structure of the novel oligomers renders precise insights into structure-activity 
relationships of the different sequences. In this way, the new polycationic building 
blocks and functional groups, like lipid moieties or crosslinking domains, for the 
assembly of the carriers can be evaluated for their effects on binding, delivery and 
intracellular release of siRNA. In contrast to most reported synthesis methods of 
polymeric delivery systems, which result in polydisperse end products, the applied 
method enables the defined assembly of various different topologies and insertion of 
functional groups at defined positions of the cationic backbone of the carriers. The 
rapid and reproducible assembly of new structures enriches the understanding on 
requirements of siRNA carriers and accelerates the discovery of highly efficient 
delivery vehicles. 
Third aim of the thesis was to exploit defined, multifunctional carrier systems, based 
on the platform of the upper mentioned monodisperse, polycationic oligomers, for 
enhanced siRNA delivery. The functionalization of siRNA polyplexes is essential for 
successful application in vivo, due to the changing biological environment during the 
delivery process. For this reason, domains for receptor targeting, shielding or with 
lytic activity were incorporated into the delivery systems, either directly linked to the 
nucleic acid or to a polycationic backbone. As targeting ligand, folic acid, targeting 
the human folic acid receptor, which is expressed on the surface of many tumor cells, 
was chosen. Receptor specific cellular attachment and internalization of targeted 
polyplexes should be demonstrated. Effective shielding should be realized by 
PEGylation of siRNA or carrier with defined starting products. The ligation of the lytic 
peptide INF7 to siRNA should facilitate enhanced endosomal release of internalized 
particles. The biological effect and specificity of each incorporated moiety alone and 
in combination with others should be examined in detail. Premise here was to 
maintain the defined character of all modified molecules during functionalization, 
rendering clear and reliable structure-activity relationships. 
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2 MATERIALS AND METHODS 
 
2.1 Chemicals, reagents and polymers 
HD O was synthesized as described previously using LMW polyethylenimine 800 Da 
and 1.6-hexanediol diacrylate (Sigma-Aldrich, Steinheim, Germany) [125]. Dimethyl 
sulfoxide (DMSO) was also obtained from Sigma-Aldrich. 
dithiobis(succinimidylpropionate) (DSP) was purchased from Thermo Fisher Scientific 
Inc. (Rockford, IL, USA). Cell culture 5 x lysis buffer and D-luciferin sodium salt were 
obtained from Promega (Mannheim, Germany). Cell culture media, antibiotics and 
fetal calf serum (FCS) were purchased from Invitrogen (Karlsruhe, Germany). Cell 
culture lysis buffer was purchased from Promega, Mannheim, Germany. 
Sequence defined oligomers, based on oligo (ethane amino) amides, were 
synthesized by solid phase supported synthesis as described previously [126, 127]. 
siRNA duplexes for the luciferase reporter gene assay were purchased from 
Dharmacon (Lafayette, CO, USA) or provided by Roche Kulmbach (Germany). 
 
Dharmacon: 
 
 LucsiRNA:  GL3 luciferase 
    5’-CUUACGCUGAGUACUUCGA-3’ (sense) 
 siControl:  nontargeting control 
    5’-AUGUAUUGGCCUGUAUUAG-3’ (sense) 
Roche Kulmbach: 
 
 GFP siRNA:  5'-AuAucAuGGccGAcAAGcAdTsdT-3' (sense) 
    5'-UGCUUGUCGGCcAUGAuAUdTsdT-3' (antisense) 
    (small letters: 2’methoxy-RNA; s: phosphorothioate) 
 Control siRNA: 5’-AuGuAuuGGccuGuAuuAGdTsdT-3’ (sense) 
    5‘-CuAAuAcAGGCcAAuAcAUdTsdT-3‘(antisense) 
 Cy5-siRNA:  (Cy5)-5’-cuuAcGcuGAGuAcuucGAdTsdT-3’ (sense) 
    5’-UCGAAGuACUcAGCGuAAGdTsdT-3’ (antisense) 
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 AHA1 siRNA: 5’-GGAuGAAGuGGAGAuuAGudTsdT-3’ (sense) 
    5’-ACuAAUCUCcACUUcAUCCdTsdT-3’ (antisense) 
 
As buffer and solvent HBG (HEPES-buffered glucose solution: 20 mM HEPES, 5% 
glucose, pH 7.4) was used. 
Human folate receptor (FOLR-1) antibody conjugated to Allophycocyanine was 
purchased from R&D Systems (U.K.). 
High Pure RNA Tissue KitTM, Transcriptor High Fidelity cDNA Synthesis KitTM, UPL 
Probes, Probes Master and primers for quantitative real time PCR were obtained 
from Roche Applied Science, Germany. 
 
2.2 Polyplex formation 
Polyplex formulations were prepared as follows (unless otherwise mentioned): siRNA 
and the calculated amount of polymer, either w/w (weight to weight) or N/P 
(protonable nitrogen to phosphate) molar ratio, were diluted with HBG buffer in 
separate Eppendorf tubes. The polycation solution was added to the siRNA solution, 
rapidly mixed by pipetting up and down (at least five times) and incubated for 40 
minutes at room temperature in order to form the polyplexes. 
 
2.3 Lateral stabilization of HD-O polyplexes via crosslinking 
Lateral crosslinking of the polyplexes was performed by adding indicated amounts of 
DSP (2 mM solution in DMSO) to the prepared polyplexes, with an additional 
incubation time of 30 minutes. The indicated different ratios of crosslinker are 
reported as a molar ratio between crosslinker (DSP) and HD-O amine groups, 
assuming that HD-O contains 54 amines per molecule with an average molecular 
weight of 4138 Da. 
 
Materials and methods                                                                                            
 
 
21 
2.4 Biophysical characterization 
2.4.1 Ethidium bromide assay 
The ability of cationic polymers to compact siRNA was studied using an ethidium 
bromide (EtBr) assay. Intercalation of EtBr into free siRNA strongly enhances 
fluorescence of EtBr. Binding of siRNA to polymers displaces the intercalated EtBr, 
leading to a significant decrease of fluorescence intensity. 
Polymer solution was added stepwise to the solution of siRNA (10 μg/mL) in 1 ml 
HBG containing EtBr (0.4 μg/mL). After each step, the fluorescence intensity was 
monitored (λex=510nm, λem=590nm) using a Cary Eclipse fluorescence 
spectrophotometer (Varian GmbH, Germany). The fluorescence intensity of the EtBr 
solution in the presence of free nucleic acid corresponded to 0% condensation, 
whereas the fluorescence intensity without nucleic acid corresponded to 100% 
condensation. 
 
2.4.2 Agarose gel shift assay 
A 2% agarose gel was prepared by dissolving agarose in TBE buffer (trizma base 
10.8 g, boric acid 5.5 g, disodium EDTA 0.75 g and 1 L of water). GelRed® was 
added for the detection of nucleic acid. Polyplexes, containing 500 ng of siRNA in 20 
µL HBG and loading buffer (prepared from 6 mL of glycerine, 1.2 mL of 0.5 M EDTA, 
2.8 mL of H2O, 0.02 g xylene cyanol) were placed into the sample pockets. 
Electrophoresis was performed at 80 V for 40 minutes. 
 
2.4.3 Particle size and Zeta potential measurement 
Particle size and Zeta potential of siRNA formulations was measured by dynamic 
laser-light scattering using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, U.K.). siRNA polyplexes (10 µg siRNA) were prepared in 20 mM 
HEPES pH 7.4 buffer and diluted in HEPES pH 7.4 buffer just before measurement. 
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2.4.4 Ellman`s assay 
The Ellman assay is a colorimetric assay used to quantify the number or 
concentration of thiol groups in a sample. With the help of this assay the formation of 
disulfides during polyplex incubation time can be monitored. The reaction between 
Ellman’s reagent (5,5′-dithiobis(2-nitrobenzoic acid), DTNB) and the free thiol groups 
present in the polymer sample results in the formation of the yellow dianion NTB2-, 
which can be quantified colorimetrically. 4 mg of DTNB dissolved in 1 mL of the 
corresponding Ellman’s buffer (0.2 M Na2HPO4 with 1 mM EDTA at pH 8.0) was used 
as stock solution. A DTNB working solution was produced by diluting the stock 
solution 1:40 in Ellman`s buffer. For UV/VIS absorption measurement this DTNB 
working solution was taken as blank. A standard curve with L-cysteine dilutions was 
created before each set of measurements. Polymer solutions or corresponding 
siRNA polyplexes (different N/P ratios with in vitro siRNA concentrations of 370 nM) 
were prepared in HBG pH 7.4 or pH 8.4 and incubated at room temperature or 37 °C. 
At indicated time points, aliquots of the solutions were diluted with the DTNB working 
solution. After 15 minutes at 37 °C the solutions were measured at 412 nm and the 
concentration of the free thiols at 0 minutes was set 100%. 
 
2.5 Biological characterization 
2.5.1 Cell culture 
Mouse neuroblastoma Neuro2A cells, Neuro2A/eGFPLuc and human hepatoma 
HepG2/eGFPLuc cells, both stably transfected with the eGFPLuc gene, were grown 
in Dulbecco’s modified Eagle’s medium (DMEM). Human prostate carcinoma DU-
145/eGFPLuc and human cervix carcinoma KB/eGFPLuc cells, both stably 
transfected with the eGFPLuc gene, were grown in RPMI-1640 medium. Human 
hepatoma HUH7/eGFPLuc cells, stably transfected with the eGFPLuc gene, were 
grown in HAM`s 12 / DMEM (50%/50%) medium. All media were supplemented with 
10% FCS, 4 mM stable glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin. 
All cultured cells were grown at 37°C in 5% CO2 humidified atmosphere. 
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2.5.2 Luciferase gene silencing 
Gene silencing experiments were performed using 0.5 µg/well (unless otherwise 
mentioned) of either GFP-siRNA or Luc-siRNA for silencing of the eGFPLuc protein, 
or control-siRNA as control. siRNA delivery was performed in 96-well plates with 5 × 
103 cells per well in triplicate. Cells were seeded 24 hours prior to transfection and 
then medium was replaced with 80 μL fresh growth medium containing 10% FCS. 
Transfection complexes for siRNA delivery (20 μL formed in HBG) were added to 
each well and incubated at 37 °C for 48 hours (unless otherwise mentioned). After 
transfection, cells were treated with 100 μL cell lysis buffer (Promega, Mannheim, 
Germany). Luciferase activity in the cell lysate was measured from a 35 µl aliquot of 
the lysate using a luciferase assay kit (100 μL Luciferase Assay buffer, Promega, 
Mannheim, Germany) and a Centro LB 960 plate reader luminometer (Berthold 
Technologies, Germany). The relative light units (RLU) are presented as percentage 
of the luciferase gene expression obtained with buffer treated control cells. 
 
2.5.3 Cell viability assay (MTT) of plain polymers 
Neuro2A/eGFPLuc cells were seeded into 96-well plates at a density of 5 × 103 
cells/well. After 24 hours, culture medium was replaced with 80 μL fresh growth 
medium containing 10% FCS. Serial dilutions of polymer stock solutions (in 20 μL 
HBG) were added. All studies were performed in triplicates. For Neuro2A/eGFPLuc 
cells, 10 μL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (5 
mg/ml) were added 48 hours after polymer addition. After an incubation time of two 
hours, unreacted dye and medium were removed. The purple formazan product was 
dissolved in 100 μL/well dimethyl sulfoxide and quantified by a plate reader (Tecan, 
Groedig, Austria) at 590 nm with background correction at 630 nm. The relative cell 
viability (%) relative to control wells containing cell culture medium with 20 μL buffer 
was calculated by [A] test / [A] control × 100. 
 
2.5.4 Erythrocyte leakage assay 
Fresh, citrate buffered murine blood was washed with phosphate-buffered saline 
(PBS). The washed murine erythrocyte suspension was centrifuged and the pellet 
was diluted to 5 x 107 erythrocytes per ml with PBS (pH 7.4, 6.5 and 5.5). A volume 
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of 75 μl of erythrocyte suspension and 75 μl of polymer solution were added to each 
well of a V-bottom 96-well plate (NUNC, Denmark), resulting in a final concentration 
of 2.5 µM polymer per well. The plates were incubated at 37 °C under constant 
shaking for one hour. After centrifugation, 80 µl of the supernatant was analyzed for 
hemoglobin release at 405 nm using a microplate plate reader (Spectrafluor Plus, 
Tecan Austria GmbH, Grödig, Austria). Control wells contained buffer with 1 % Triton 
X-100 for 100% lysis. 
 
2.5.5 Serum stability assay 
A 2% agarose gel was prepared containing GelRed® as described above. Polyplexes 
(N/P 12) containing 200 μg/ml of siRNA in 12.5 μL 20 mM HEPES (pH 7.4) were 
incubated at room temperature for 30 minutes. Fetal bovine serum (FBS) in different 
concentrations (0, 10, 50 and 90% v/v) was added to the polyplexes for 15 minutes. 
An aliquot of the samples containing 500 ng siRNA and loading buffer (containing 
xylene cyanol) were placed into the sample pockets. Electrophoresis was performed 
at 80 V for 40 min. 
 
2.5.6 Flow cytometry 
2.5.6.1 Cellular uptake of untargeted polyplexes 
Neuro2A or HUH-7 cells were seeded into 24-well plates at a density of 5 × 104 
cells/well. After 24 hours, culture medium was replaced with 400 μL fresh growth 
medium containing 10% FCS. Transfection complexes for siRNA delivery (containing 
2.5 μg Cy5-labeled siRNA) were added to each well and incubated at 37 °C for 4 
hours. Subsequently, cells were washed twice with 500 μl PBS, containing 100 I.U. of 
heparin per ml, for 15 minutes to detach any polyplexes sticking to the cell surface. 
Cells were detached with trypsin/EDTA, taken up in PBS with 10% FCS and flow 
cytometry was performed using a FACSCantoTM II flow cytometer (Becton Dickinson) 
or a Cyan™ ADP flow cytometer (Dako, Hamburg, Germany). Cellular uptake was 
assayed by excitation of Cy5 dye at 635 nm and detection of emission at 665 nm. To 
discriminate between viable and dead cells as well as for exclusion of doublets, cells 
were appropriately gated by forward/sideward scatter and pulse width, 
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counterstained with propidium iodide or DAPI and 1 x 104 gated events per sample 
were collected. Data were recorded by BD FACS DivaTM software or Summit™ 
software (Summit, Jamesville, NY, USA) and evaluated using FlowJo® software. 
 
2.5.6.2 Cellular association of targeted polyplexes 
KB cells were seeded into 24-well plates at a density of 5 × 104 cells/well. After 24 
hours, culture medium was replaced with 400 μL fresh growth medium containing 
10% FCS and 400 µl fresh growth medium containing 10% FCS, saturated with folic 
acid, respectively. Next cells were incubated on ice for 30 minutes. Transfection 
complexes for siRNA delivery (Cy5-labeled INF-siRNA) at an N/P ratio of 16 (100 μL 
in HBG) were added to each well and incubated at 4 °C for 30 minutes (final siRNA 
concentration: 200 nM). Subsequently, cells were washed twice with PBS. Cells were 
detached with trypsin/EDTA and taken up in PBS with 10% FCS. Flow cytometry was 
performed as described in 2.5.6.1. 
 
2.5.6.3 Cellular uptake of targeted polyplexes 
KB or HUH-7 cells were seeded into 24-well plates at a density of 5 × 104 cells/well. 
After 24 hours, culture medium was replaced with 400 μL fresh growth medium 
containing 10% FCS. Transfection complexes for siRNA delivery (Cy5-labeled INF-
siRNA) at an N/P ratio of 16 (100 μL in HBG) were added to each well and incubated 
at 37 °C for 30 minutes (final siRNA concentration: 200 nM). Subsequently, cells 
were washed twice with PBS. Cells were detached with trypsin/EDTA and taken up in 
PBS with 10% FCS. Flow cytometry was performed as described in 2.5.6.1. 
 
2.5.6.4 Cellular uptake of targeted siRNA 
KB or Neuro2A cells were seeded into 24-well plates at a density of 5 × 104 
cells/well. After 24 hours, culture medium was replaced with 400 μL fresh growth 
medium containing 10% FCS. Plain Cy5-labeled siRNA (2.5 μg in 100 μL HBG) or 
transfection complexes (N/P ratio of 6 and 12 in 100 μL HBG, containing 2.5 μg Cy5- 
labeled siRNA) were added to each well and incubated at 37 °C for 30 minutes. 
Subsequently, cells were washed twice with 500 μL PBS. Cells were detached with 
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trypsin/EDTA and taken up in PBS with 10% FCS. Flow cytometry was performed as 
described in 2.5.6.1. 
 
2.5.7 Fluorescence microscopy 
2.5.7.1 Folic acid receptor determination 
KB or HUH-7 cells were seeded into 8 well Labtek™ chamberslides at a density of 2 
× 104 cells/well. 24 hours after seeding cells were exposed to 5 µl of the FOLR-1-
antibody (conjugated to Allophycocyanin) directed against the human folate receptor 
1 for 30 minutes at room temperature. Unbound antibody was removed by washing 
the cells twice with PBS and nuclei were stained with Hoechst 33342 dye. A Zeiss 
Axiovert 200 fluorescence microscope was used to collect the images and data were 
analyzed and processed by AxioVision LETM software. 
 
2.5.7.2 Cellular uptake of untargeted polyplexes 
Neuro2A or HUH-7 cells were seeded into 8 well Labtek™ chamber slides at a 
density of 2 × 104 cells/well. After 24 hours culture medium was replaced with 240 μL 
fresh growth medium, containing 10% FCS. Transfection complexes for siRNA 
delivery (1.5 µg siRNA including 20% Cy5-labeled siRNA ) at indicated N/P ratios (60 
µl in HBG) were added to each well and incubated at 37 °C for 24 hours. 
Subsequently, a washing step with PBS, containing 100 I.U. heparin per ml, was 
performed for 20 minutes. Cell nuclei were stained with Hoechst 33342 dye and in 
the case of HUH-7 cells endo-/lysosomes were stained with Lysotracker™ green (50 
nM) for 30 minutes. Cellular uptake was assayed by detection of Cy5 (excitation 635 
nm, emission 665 nm) and Lysotracker green (excitation 504 nm, emission 511 nm). 
A Zeiss Axiovert 200 fluorescence microscope was used to collect the images and 
data were analyzed and processed by AxioVision LETM software. 
 
2.5.7.3 Cellular uptake of targeted polyplexes 
KB or HUH-7 cells were seeded into 8 well Labtek chamber slides at a density of 2 × 
104 cells/well. After 24 hours culture medium was replaced with 240 μL fresh growth 
medium, containing 10% FCS. Transfection complexes for siRNA delivery (Cy5-
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labeled INF-siRNA) at an N/P ratio of 16 (60 μL in HBG) were added to each well and 
incubated at 37 °C for 30 minutes (final siRNA concentration: 200 nM). 
Subsequently, cells were washed twice with 500 μL PBS and cell nuclei were stained 
with Hoechst 33342 dye. Cellular uptake was assayed by excitation of Cy5 at 635 nm 
and detection of emission at 665 nm. A Zeiss Laser Scanning Microscope LSM510 
Meta was used to collect the images and data were analyzed and processed by 
AxioVision LETM software. 
 
2.5.7.4 Cellular uptake of targeted siRNA 
KB or Neuro2A cells were seeded into 8 well Labtek chamber slides at a density of 2 
× 104 cells/well. After 24 hours culture medium was replaced with 240 μL fresh 
growth medium, containing 10% FCS. Cy5-labeled siRNA (1.5 μg in 60 μL HBG) was 
added to each well and incubated at 37 °C for 30 minutes. Subsequently, cells were 
washed twice with 500 μL PBS and cell nuclei were stained with Hoechst 33342 dye. 
Cellular uptake was assayed by excitation of Cy5 at 635 nm and detection of 
emission at 665 nm. A Zeiss Axiovert 200 fluorescence microscope was used to 
collect the images and data were analyzed and processed by AxioVision LETM 
software. 
 
2.5.8 Qantitative real-time PCR (RT-qPCR) 
Neuro2A/eGFPLuc cells were seeded into 24-well plates at a density of 3 × 104 
cells/well. After 24 h, culture medium was replaced with 400 µl fresh growth medium 
containing 10% FCS. Transfection complexes for siRNA delivery (100 μL in HBG) 
were added to each well (2.5 µg siRNA / well) and incubated at 37 °C without 
medium change. 48 hours after transfection total RNA was isolated using High Pure 
RNA Tissue KitTM (Roche, Germany) and transcribed with the Transcriptor High 
Fidelity cDNA Synthesis KitTM (Roche, Germany) according to manufacturer’s 
protocol. Quantitative real-time PCR was performed using UPL Probes and Probes 
Master (both Roche, Germany) on a LightCycler 480TM system (Roche, Germany) 
with GAPDH as control. Primers used include ACTB (ready to use Universal Probe 
library assay Roche); AHA1 (UPL Probe #43) left: 
CAATGAATGGAGAGTCAGTAGACC, right: GCCTGGGTTTTTGAAGGAG. 
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Experiments were performed in triplicates and the achieved average CT values were 
normalised against control as ΔCT. AHA1 expression pattern in AHA1-siRNA and 
control-siRNA treated samples were compared to HBG treated cells 
 
2.6 Statistical analysis 
Results are presented as mean ± standard deviation (SD). Statistical significance of 
differences was evaluated by one-way analysis of variance (ANOVA). P-values < 
0.05 were considered significant. Statistics were performed with Graph Pad Prism 
5.0®. 
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3 RESULTS 
 
3.1 Lateral stabilization of siRNA polyplexes via DSP crosslinking 
for efficient siRNA delivery 
3.1.1 Design of crosslinked HD-O polyplexes 
The pseudodendritic, biodegradable polymer HD-O was reported to effectively 
transfect plasmid DNA (pDNA) in vitro and in vivo with good biocompatibility [125]. A 
polyplex surface crosslinking strategy with the amine reactive crosslinker dithiobis-
(succinimidylpropionate) (DSP) and disuccinimidyl suberate (DSS), respectively, 
further improved the stability of DNA polyplexes, which is particularly important for in 
vivo application, but was not strictly required for efficacy [128]. The findings for pDNA 
transfection cannot always be transferred to siRNA delivery [129]. Due to the much 
smaller size of the siRNA duplex compared to pDNA, the siRNA polyplexes lack 
stability in an electrolyte and protein containing environment. 
Plain HD-O/siRNA polyplexes showed very moderate gene silencing ability in serum 
containing medium. pDNA polyplexes owe their stability largely to numerous 
electrostatic, entropy-driven interelectrolyte interactions which during polyplex 
formation condensate pDNA into a compact particle. Because of the much smaller 
size of siRNA (usually 21 to 23 base pairs) compared to pDNA (1 to 10 kbp) and 
additionally the small size of HD-O polymers (~ 4100 Da) the resulting particles are 
not as stable as HD-O/DNA polyplexes. 
 
Scheme 1: Surface crosslinking reaction of HD-O polyplexes with the homobifunctional, amine 
reactive crosslinker DSP. 
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Therefore the previously applied crosslinking strategy for DNA was also applied for 
siRNA polyplexes (Scheme 1). The formed polyplexes of HD-O and siRNA were 
laterally stabilized by adding a fixed percentage of the crosslinker DSP. This 
homobifunctional crosslinker with reactive NHS esters at each end readily reacts with 
amino groups of the polymer on the surface of the polyplexes. The fixed percentage 
of the crosslinker was optimized to a molar ratio of 0.05/1 between crosslinker and 
the amines of HD-O, assuming that HD-O contains about 54 amines per molecule 
with an approximate molecular weight of 4100 Da. 
 
3.1.2 Effect of lateral stabilization on siRNA delivery in vitro 
HD-O polyplexes proved ineffective in siRNA delivery. Therefore particle optimization 
was performed by crosslinking the polyplexes and finding the optimum weight to 
weight balance between polymer and siRNA (Figure 5). 
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Figure 5: Gene silencing ability of HD-O polyplexes crosslinked with 0.05/1 DSP and increasing 
weight/weight ratios of polymer/siRNA in Neuro2A-eGFPLuc cells. Black: Luc-siRNA, white: control-
siRNA. 
 
Figure 5 illustrates that within a window between w/w 0.5/1 and 2/1 the crosslinked 
particles mediate effective gene silencing in the murine neuroblastoma Neuro2A cell 
line. Luciferase activity was determined for cells treated either with Luc-siRNA 
(directed against the eGFPLuc fusion protein) or with control-siRNA and compared 
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with the luciferase activity of buffer treated control cells. As an example, a w/w ratio 
of 1 plus crosslinking reproducibly resulted in more than 90% silencing of the 
luciferase signal without unspecific knockdown or toxicity, indicated by the absence 
of gene silencing in the control-siRNA treated group. 
Further proof for the good biocompatibility of the linker-stabilized polyplexes was 
provided by a simultaneously performed MTT test (Figure 6). 
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Figure 6: Cell viability of Neuro2A-eGFPLuc cells 48 hours after treatment with 0.05/1 DSP 
crosslinked siRNA polyplexes (at indicated w/w ratios). 
 
A very moderate decrease of cell viability was detected for the crucial w/w ratios of 
1/1 and 1.5/1. Significant signs of toxicity were observed only from a w/w ratio of 2/1 
and higher (data not shown). 
In order to optimize the DSP linker ratio, several DSP concentrations were reacted 
with HD-O polyplexes at the optimum w/w ratio of 1/1. Gene silencing efficiency of 
the crosslinked polyplexes was tested in the luciferase reporter assay (Figure 7). It 
could be shown that 0.05/1 is the most effective ratio. DSP concentrations below this 
ratio are insufficient and do not enhance gene silencing efficiency. Concentrations 
above 0.1/1 lead to aggregation of the particles, probably by increased 
interparticulate crosslinking between the polyplexes. An excess of linker leads to 
complete loss of gene silencing activity. 
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Figure 7: Effect of increasing crosslinker concentrations on gene silencing ability of HD-O polyplexes 
(w/w 1/1) in Neuro2A-eGFPLuc cells. Black: Luc-siRNA, white: control-siRNA. 
 
Efficiency of the optimized crosslinked polyplexes was also determined in a different 
cell line, the human hepatoma HUH-7 cell line (Figure 8). 
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Figure 8: Comparison of the gene silencing ability of HD-O polyplexes (w/w 1/1) without and with 
0.05/1 DSP crosslinking in Neuro2A-eGFPLuc and HUH7-eGFPLuc cells. Black: Luc-siRNA, white: 
control-siRNA. 
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The results of the luciferase reporter gene assay for HUH-7 cells are comparable to 
those obtained with Neuro2A cells. A strong increase of luciferase knockdown after 
lateral stabilization of the polyplexes with DSP was observed. In both cell lines, the 
tested ratios of polymer and crosslinker showed no signs of unspecific knockdown in 
the control-siRNA treated group. 
 
3.1.3 Biophysical characterization 
The optimized polyplexes with a weight to weight ratio of 1/1 and 1.5/1 and a DSP 
crosslinker ratio of 0.05/1 were examined for size and Zeta potential in comparison to 
their unmodified counterparts (Table 1). 
 
Table 1: Particle size and Zeta potential of HD-O/siRNA polyplexes (w/w 1/1 or 1.5/1) with and without 
DSP crosslinking. 
HD-O w/w Size [nm] Zeta [mV]
- 1/1 113 ± 3 27,6 ± 0,4
+ 0.05/1 DSP 1/1 197 ± 3 20,1 ± 0,7
- 1,5/1 87 ± 1 33,1 ± 0,2
+ 0.05/1 DSP 1,5/1 127 ± 1 30,8 ± 0,5
 
 
Linker-stabilized nanoparticles showed a slightly increased size compared to 
nonstabilized polyplexes but were still smaller than 200 nm. The measured Zeta 
potential decreased for both measured weight to weight ratios after crosslinking. This 
decrease is caused by the loss of surface amines in the polyplex through the 
crosslinking reaction. Amines from the polymer HD-O on the polyplex surface react 
with DSP to form stable amide bonds, which cannot be protonated any more and 
thus cannot contribute to a positive surface charge of the particles. The decrease of 
the Zeta potential is an indicator for successful surface crosslinking by DSP. 
Stability of the polyplexes is essential for successful delivery of siRNA into the 
cellular cytosol. The stability of linker-stabilized and nonstabilized polyplexes at 
increasing w/w ratios was determined in the agarose gel shift assay (Figure 9). The 
electrophoresis assay revealed that both crosslinked and uncrosslinked polyplexes 
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retain the majority of siRNA in the loading pocket from a weight to weight ratio of one 
onward. 
 
HD-O
+ 0,05/1 DSP
w/w-ratio1/10 1,5/1 2/1 2,5/1
HD-O
w/w-ratio1/10 1,5/1 2/1 2,5/1
 
Figure 9: Agarose gel shift assay of crosslinked (0.05/1 DSP) and uncrosslinked HD-O polyplexes at 
rising w/w ratios. 
 
A small difference between stabilized and unstabilized polyplexes is observable at 
w/w 1/1: the DSP crosslinking slightly improves siRNA retention, supporting the 
assumption that surface crosslinking enhances the stability of the polyplexes. 
 
3.1.4 Cellular uptake of linker-stabilized polyplexes 
The gene silencing assay demonstrated successful silencing of luciferase protein by 
linker-stabilized HD-O/siRNA polyplexes, targeting the eGFPLuc fusion protein. In 
order to support this finding, internalization of the polyplexes was determined by flow 
cytometry. Polyplexes were spiked with fluorescently labeled Cy5-siRNA and the 
amount of Cy5 positive cells compared to buffer treated control cells was detected 
(Figure 10 and 11). Although nonstabilized particles showed a moderate uptake 
(mean: 7.1% ± 2.5% positive cells, Figure 11), a substantial shift of the Cy5 signal 
was detectable after cells had been treated with stabilized polyplexes (mean: 43.6% 
± 5.4% positive cells, Figure 11) already at the short 1 h incubation time. 
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Figure 10: Flow cytometric assay of polyplex uptake at 1 hour after transfection (single measurement 
as representative for three individual measurements; for summary of triplicates see Figure 11). HD-O 
polyplexes were spiked with 20% fluorescently labeled (Cy5) siRNA. A) Buffer treated control. B) HD-
O polyplexes (w/w 1/1). C) HD-O polyplexes (w/w 1/1) + 0.05/1 DSP. 
 
The moderate uptake of nonstabilized polyplexes in this experiment is consistent with 
the results of the luciferase reporter gene assay (Figure 8), in which also only 
moderate gene silencing is detectable for both tested cell lines. 
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Figure 11: Flow cytometric assay of polyplex uptake at 1 hour after transfection; summary of three 
individual measurements for each formulation (p < 0.0005). White: HD-O polyplexes (w/w 1/1). Black: 
HD-O polyplexes (w/w 1/1) + 0.05/1 DSP. 
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3.1.5 Knockdown evaluation on mRNA level 
Target gene silencing can be proven on protein level, as shown with the luciferase 
reporter gene assay, or by direct measurement of the levels of targeted mRNA. 
Successful siRNA mediated gene silencing leads to decreased mRNA levels and in 
consequence to a reduced amount of protein. In this experiment the gene encoding 
for AHA1, activator of 90 kDa heat shock protein ATPase [130], was chosen for 
evaluation of mRNA knockdown with quantitative real time PCR. AHA1 plays no 
critical role in cell survival, which makes it an ideal target for unbiased mRNA 
knockdown experiments. In order to determine successful silencing of this 
endogenous gene, the level of AHA1 mRNA after treatment with AHA1-siRNA 
containing polyplexes was verified. As an internal standard the stably expressed 
house keeper gene ACTB was chosen (Figure 12). 
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Figure 12: AHA1 mRNA levels in Neuro2A-eGFPLuc cells 48 hours after treatment with HD-O 
polyplexes (w/w 1/1) +/- 0.05/1 DSP. Gray: buffer control, white: AHA1 siRNA, black: control siRNA. 
qPCR experiments were performed by Daniel Edinger. 
 
Significant differences in AHA1 expression between cells treated with HD-O/AHA1-
siRNA polyplexes with or without lateral stabilization were detected. The 
nonstabilized particles achieved a moderate knockdown of 39%, whereas treatment 
with DSP crosslinked polyplexes resulted in 85% AHA1 gene knockdown. Application 
of control siRNA did not affect AHA1 expression for both formulations. 
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3.2 Solid phase derived, precise oligomers for siRNA delivery 
Polymers represent an interesting class of delivery vehicles for nucleic acids because 
they can be tailored exactly to the individual requirements of the payload and 
functionalities like targeting moieties or shielding agents can be incorporated. 
However, the synthesis of such polymers with the help of solution chemistry yields 
polydisperse products due to incomplete coupling reactions and high amounts of 
impurities along with the desired product. Purification of the polymers, especially of 
those with additional functional groups, is difficult, time consuming and often only 
possible to a certain extent. A promising solution to this problem is a solid phase 
supported synthesis method for the design of monodisperse, sequence defined 
polymers for nucleic acid delivery [127, 131]. 
Employing this synthesis strategy, our group assembled several hundred oligomeric 
structures, with the aim of finding suitable siRNA delivery agents and rendering clear 
and reliable structure-activity relationships between polymer design and delivery 
efficacy. 
 
3.2.1 Design of sequence defined oligomers based on oligo (ethane 
amino) amides 
The new solid phase derived oligomers were synthesized from a set of building 
blocks, see Scheme 2. New artificial oligoamino acids (AA) form the backbone of the 
oligomers: Ptp, Stp, Gtp and Gtt. They contain tetraethylenpentamine (tp) or 
triethylentetramine (tt), coupled to succinic, glutaric or phthalic acid. In the past, 
polymers like polyethylenimine have shown successful nucleic acid delivery [70, 132-
134]. The essential subunit of these structures, the 1,2-diaminoethane motif, enables 
the binding of nucleic acid and facilitates endosomal escape through interaction with 
the vesicle membrane and the proton sponge effect [32, 67]. Because of these 
interesting features, this motif was also incorporated into the new building blocks. For 
the introduction of lytic domains, the incorporation of fatty acids with increasing chain 
length and varying degrees of saturation at predefined positions within the oligomers 
was examined. Additionally, selected natural amino acids were used: lysine served 
as a branching point during polymer synthesis, cysteines were utilized for the 
Results                                                                                            
 
 
38 
formation of stabilizing disulfide bonds during polyplex formation and alanine was 
employed for replacing cysteines in control oligomers. 
Scheme 2: Building blocks for oligomer synthesis. Artificial amino acids Ptp, Stp, Gtp, Gtt without (X = 
Y = H) or with protective groups (X = Fmoc, Y = Boc); fatty acids butyric acid (ButA), caprylic acid 
(CapA), myristic acid (MyrA), stearic acid (SteA), oleic acid (OleA), linolic acid (LinA); natural amino 
acids cysteine (C) and alanine (A) without (X = Z = H) or with protective groups (X = Fmoc; Z = 
triphenylmethyl); natural amino acid lysine (K) without (X = H) or with protective group (X = Fmoc or 
dde, depending on synthesis strategy). 
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Together with the new building blocks, solid phase supported synthesis enabled the 
construction of a broad variety of oligomeric structures. Scheme 3 shows the four 
main molecular topologies that were assembled and evaluated: a three-armed 
structure and three fatty acid containing structures (T-shape, i-shape, U-shape). 
The three-armed structure is built up of three identical arms, consisting of the new 
artificial amino acid building blocks, with a terminal cysteine in each arm and a lysine 
in the middle as branching point. Preliminary experiments had shown that the 
cysteine residues and their crosslinking potential upon siRNA polyplex formation are 
critical for particle stability, cellular uptake and gene silencing performance [127]. 
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Scheme 3: Sketch of the oligomer shapes: three-armed structure with a lysine as branching point; T-
shape with two fatty acids incorporated in the middle of the polymer backbone; i-shape with two fatty 
acids on one side of the backbone; U-shape with two fatty acids at each end of the polymer backbone. 
“+” in red represents a cationic oligoamino acid building block (Ptp, Stp, Gtp, Gtt). 
 
 
The other three structures all contain fatty acids at defined positions of the oligomer 
backbone: the T-shape has two vicinal fatty acids located in the middle of the 
oligomer, the i-shape has the two fatty acids attached to one side of the oligomer and 
the U-shape has two fatty acids linked to each end of the oligomer chain. Various 
lipid moieties were screened, studying the effect of different locations of the lipid 
components within the oligomer and the hydrophilic/lipophilic balance, optimal for 
stable and effective siRNA nanoparticles. Optionally, cysteines were incorporated at 
each end of the fatty acid containing oligomers. A list of sequences of all discussed 
oligomers can be found in Table 2 (see below). 
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Table 2: List of tested oligomers. 
polymer sequencetopologypolymer ID
A-Gtp-Gtt-Stp-A-K-LinA2i-shape379
(A-Stp-Stp-Stp)2]K-Stp-Stp-Stp-Athree-arm387
229 i-shape C-Stp-Stp-Stp-C-K-LinA2
510 i-shape C-Ptp-Ptp-Ptp-C-K-LinA2
226 i-shape C-Gtp-Gtp-Gtp-C-K-LinA2
228 i-shape C-Gtt-Gtt-Gtt-C-K-LinA2
230 i-shape C-Gtp-Gtt-Stp-C-K-LinA2
386 three-arm (C-Stp-Stp-Stp)2]K-Stp-Stp-Stp-C
515 three-arm (C-Ptp-Ptp-Ptp)2]K-Ptp-Ptp-Ptp-C
514 three-arm (C-Gtp-Gtp-Gtp)2]K-Gtp-Gtp-Gtp-C
513 three-arm (C-Gtt-Gtt-Gtt)2]K-Gtt-Gtt-Gtt-C
413 T-shape C-Stp-Stp-K(K)-Stp-Stp-C
461 T-shape C-Stp-Stp-K(K-ButA2)-Stp-Stp-C
68 T-shape C-Stp-Stp-K(K-CapA2)Stp-Stp-C
48 T-shape C-Stp-Stp-K(K-MyrA2)Stp-Stp-C
462 T-shape C-Stp-Stp-K(K-SteA2)Stp-Stp-C
49 T-shape C-Stp-Stp-K(K-OleA2)Stp-Stp-C
463 T-shape C-Stp-Stp-K(K-LinA2)Stp-Stp-C
51 i-shape C-Stp-Stp-Stp-C-K
45 i-shape C-Stp-Stp-Stp-C-K-MyrA2
46 i-shape C-Stp-Stp-Stp-C-K-OleA2
197 three-arm (C-Stp)2]K-Stp-C
199 three-arm (C-Stp-Stp)2]K-Stp-Stp-C
277 three-arm (C-Stp-Stp-Stp-Stp)2]K-Stp-Stp-Stp-Stp-C
76 T-shape C-Stp-(OleA)2K]K-Stp-C
80 T-shape C-Stp-Stp-Stp-(OleA)2K]K-Stp-Stp-Stp-C
84 T-shape C-Stp-Stp-Stp-Stp-(OleA)2K]K-Stp-Stp-Stp-Stp-C
281 U-shape C-(LinA)2K]K-Stp-(LinA)2K]K-C
280 U-shape C-(LinA)2K]K-Stp-Stp-(LinA)2K]K-C
278 U-shape C-(LinA)2K]K-Stp-Stp-Stp-(LinA)2K]K-C
352 U-shape C-(LinA)2K]K-Stp-Stp-Stp-Stp-(LinA)2K]K-C
389 U-shape A-(LinA)2K]K-Stp-(LinA)2K]K-A
390 U-shape A-(LinA)2K]K-Stp-Stp-(LinA)2K]K-A
279 U-shape A-(LinA)2K]K-Stp-Stp-Stp-(LinA)2K]K-A
388 U-shape A-(LinA)2K]K-Stp-Stp-Stp-Stp-(LinA)2K]K-A
470 i-shape C-Stp-Stp-Stp-Stp-C-K-OleA2
488 U-shape K-(Stp-Stp-Stp-Stp-K-(K-OleA2)-C)2
471 i-shape C-Stp-Stp-Stp-Stp-C-K-LinA2
489 U-shape K-(Stp-Stp-Stp-Stp-K-(K-LinA2)-C)2  
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3.2.2 Influence of different cationic building blocks on gene silencing 
efficiency 
The new artificial amino acids, Ptp, Stp, Gtp, and Gtt were screened for their ability to 
bind siRNA, form stable polyplexes and mediate gene silencing (Figure 13). Two 
model oligomer topologies were chosen for testing efficiencies of the different 
incorporated artificial amino acids (aa): on the one hand, an i-shape lipopolymeric 
structure, based on three aa units and two fatty acids attached to a lysine at one side 
of the oligomer backbone, (LinA)2K-C-aa-aa-aa-C (Figure 13 left). On the other hand,  
a branched three-armed structure free of lipidic residues, consisting of three arms, 
each built up of three aa units containing a terminal cysteine, (C-aa-aa-aa)2]K-aa-aa-
aa-C, (Figure 13 right). 
Physicochemical tests show the ability of the i-shape oligomers to bind (Figure 13A) 
and compact (Figure 13B) siRNA. In the gel shift (Figure 13A left) most of the siRNA 
is retained in the gel pockets for the Stp, Ptp and Gtp building blocks even at a low 
nitrogen/phosphate (N/P) ratio of 3. Interestingly, the EtBr assay (Figure 13B left) 
revealed that the compaction ability is higher for the Stp and Gtp blocks than for Ptp 
or Gtt, but dye exclusion is much lower than for the high molecular weight linear PEI 
control polymer. Considering both assays, the binding/compaction ability of the 
building blocks in i-shape oligomers decreases in the following order: Stp > Gtp > Ptp 
> Gtt. The mixture of building blocks (Stp-Gtt-Gtp) in one oligomer had no beneficial 
effects.  
In vitro gene silencing (Figure 13C left) was determined using Neuro2A cells, stably 
expressing eGFPLuc. Treatment with eGFP siRNA polyplexes (but not control siRNA 
polyplexes) showed effective gene silencing for all tp –based amino acids (Stp, Ptp, 
Gtp). Some reduced knockdown activity was observed for the building block mixture, 
and only moderate knockdown for the oligomer with the Gtt building block (Figure 
13C left). Luciferase activity was determined for cells treated either with GFP siRNA 
(directed against the eGFPLuc fusion protein) or with control siRNA and always 
compared (in relative %) with the luciferase activity (100%) of buffer treated control 
cells (Figure 13C left). Remarkably, none of the presented structures caused 
significant toxicity, indicated by the absence of unspecific knockdown signal in the 
control siRNA treated cells. 
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Figure 13: Left: i-shape oligomers with two cysteines, two terminal LinA, and varying building blocks, 
right: three-armed oligomers with a terminal cysteine at the end of each arm. A) siRNA binding assay 
at different N/P ratios. B) Ethidium bromide exclusion assay at increasing N/P ratios. Control polymer: 
linear PEI (22 kDa). C) Gene silencing ability of polyplexes in Neuro2A-eGFPLuc cells with eGFP-
targeted siRNA or control siRNA was tested (at different nitrogen/phosphate ratios, N/P). Positive 
control: succinylated PEI (sPEI) [73]. Black: GFP-siRNA, white: control-siRNA. 
 
The ethidium bromide assay revealed a big difference between the control polymer 
linear polyethylenimine (linPEI) and the i-shape formulations. linPEI is able to form 
very compact particles, leading to a drastic decrease in fluorescent signal in this 
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assay. In contrast the i-shapes seem to form stable particles with less compact 
structure, as the fluorescent signal from EtBr / siRNA interaction only decreases to a 
maximum of 60% when oligomer is added. 
 
Table 3: Size and Zeta potential of i-shape oligomer (LinA)2K-C-aa-aa-aa-C (N/P 12) with different 
building blocks. 
Building block Size [nm] Zeta potential [mV]
Stp 182 ± 7 27,7 ± 0,2
Ptp 144 ± 2 25,6 ± 0,7
Gtp 18 ± 1 21,4 ± 1,2
Gtt 314 ± 20 26,2 ± 0,4
Gtp-Gtt-Stp 172 ± 1 26,1 ± 0,6
 
 
However, the i-shape lipopolymers effectively bind siRNA (Figure 13A left), form 
polyplexes of approximately 200 nm or smaller with a zeta potential above 20 mV at 
N/P 12 (Table 3) and mediate efficient reporter gene knockdown in serum containing 
medium (Figure 13C left), whereas linear PEI only achieves moderate knockdown, 
including unspecific knockdown due to significant toxicity at low N/P ratios (Figure 
14). 
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Figure 14: Gene silencing ability of linear PEI (22 kDa) in Neuro2A-eGFPLuc cells with eGFP-
targeted siRNA or control siRNA (at different N/P ratios). Positive control: succinylated PEI (sPEI). 
Black: GFP-siRNA, white: control-siRNA. 
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Apparently, apart from electrostatic compaction of the nucleic acid, other stabilizing 
mechanisms exist in assembly with i-shape lipopolymers, such as disulfide formation 
via cysteine crosslinking and stabilizing effects through the lipid modification (see 
below). 
For the three-arm structure (Figure 13 right), similar results were obtained: the Stp 
building block, followed by Gtp showed best physicochemical properties in agarose 
gel shift and ethidium bromide assay. Ptp and Gtt based oligomers did not bind 
siRNA to a sufficient extent (Figure 13A right). Consistently, only the three-arm 
oligomers with Stp or Gtp facilitate siRNA mediated gene silencing (Figure 13C right). 
 
3.2.3 Lipid modification at selected positions of the oligomers 
The incorporation of lipid moieties into cationic polymers can improve particle stability 
and also can introduce pH sensitive amphiphilicity, leading to enhanced membrane 
disruption at an endosomal pH of 5 to 6 and thereby enhance endosomal escape. 
We systematically tested the effect of various incorporated fatty acids differing in 
hydrocarbon chain length (from C4 to C18) and saturation. As a model oligomer 
topology, a T-shape structure with four Stp units and two terminal stabilizing 
cysteines was chosen. Two vicinal fatty acids were incorporated in the middle of the 
oligomer backbone by attachment to both alpha- and epsilon amino groups of a 
grafted lysine. Preliminary siRNA knockdown tests had shown that it was necessary 
to incorporate two fatty acids in close proximity in order to achieve effective gene 
silencing. The gene silencing assay (Figure 15A) revealed that out of the six tested 
fatty acids, the two unsaturated fatty acids with 18 carbon atoms, oleic acid and 
linolic acid, were the most effective lipid moieties. The incorporation of myristic acid 
also resulted in knockdown activity but also significant cytotoxicity. Similar results 
were obtained for i-shape structures (Figure 16) emphasizing oleic acid and linolic 
acid as most attractive hydrophobic oligomer modifications. The corresponding 
saturated C18 modification, stearylation, showed only moderate silencing activity. 
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Figure 15: A) Gene silencing ability of T-shape oligomer with different lipid moieties in Neuro2A-
eGFPLuc cells with eGFP-targeted siRNA or control siRNA (at different N/P ratios). Positive control: 
succinylated PEI (sPEI). Black: GFP-siRNA, white: control-siRNA. B) Erythrocyte leakage assay of 
plain oligomer (2.5 µM) at different pH values (white: pH 7.4, grey: pH 6.5, black: pH 5.5); leakage 
assay was performed by Christina Troiber. 
 
The erythrocyte leakage assay (Figure 15B) demonstrates the lytic effect of oligomer 
on fresh mouse erythrocytes at different pH values. Structures with ≥ C14 
modifications (myristic, stearic, oleic or linolic acid) showed pH specific behaviour 
with no or moderate lytic activity at physiological pH 7.4 and high hemolysis at 
endosomal pH 5.5, respectively. The myristic acid modification results in a potent 
lysis activity already at pH 6.5 which correlates with the observed cytotoxicity of this 
oligomer. 
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Figure 16: Influence of different lipid moieties on the gene silencing ability of an i-shape oligomer, 
(FatA)2K-C-Stp-Stp-Stp-C, in Neuro2A-eGFPLuc cells with eGFP-targeted siRNA or control siRNA (at 
different N/P ratios). Positive control: succinylated PEI (sPEI). Black: GFP-siRNA, white: control-
siRNA. 
 
3.2.4 Effect of chain length variation of the oligomers 
The effect of the chain length of the oligomers on transfection efficiency is another 
interesting aspect which has to be considered in polymer design. In this library 
different shapes were tested with increasing numbers of Stp building blocks, from 
one to four units in each arm (Figure 17). Three-arm and T-shape structures with 
only one Stp unit in each arm are ineffective in siRNA delivery, whereas the very 
lipophilic U-shape oligomer with one Stp unit per molecule, with or without cysteines, 
shows activity. All three shapes enabled gene silencing when two or more Stp units 
per arm were assembled. Surprisingly, a further increase above two Stp units per 
arm did not enhance transfection efficiency but also did not increase toxicity of the 
oligomers. 
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Figure 17: Gene silencing ability of oligomers with increasing chain length (1 to 4 Stp units in each 
arm) in Neuro2A-eGFPLuc cells with eGFP-targeted siRNA or control siRNA (at different N/P ratios). 
A) Three-armed oligomers with terminal cysteines B) T-shape oligomers with two oleic acids and 
terminal cysteines C) U-shape oligomers with four linolic acids and terminal cysteines D) U-shape 
oligomers with four linolic acids without terminal cysteines. Positive control: succinylated PEI (sPEI). 
Black: GFP-siRNA, white: control-siRNA. 
 
3.2.5 Disulfide stabilization of polyplexes 
Due to the far fewer negative charges of siRNA compared to pDNA, electrostatic 
interaction between nucleic acid and the positively charged polymer in the polyplexes 
does not provide sufficient stability of the particles. Apart from additional hydrophobic 
modification of polymers, which also improves polyplex stability, the introduction of 
cysteines for disulfide crosslinking is a versatile way to increase particle stability. 
Especially for in vivo applications, particle stability might be essential for successful 
delivery. As an example, the disulfide formation during polyplex incubation time of the 
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three-armed oligomer 386 with a terminal cysteine in each arm was monitored 
(Figure 18). 
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Figure 18: Thiol oxidation kinetics of three-armed oligomer 386, (C-Stp-Stp-Stp)2]K-Stp-Stp-Stp-C, 
during polyplex formation. The oligomer was incubated without siRNA (at a concentration 
corresponding to N/P 20/1) or with siRNA at different N/P ratios (siRNA concentrations as in cell 
culture: 370 nM). 
 
After 40 minutes of polyplex formation time approximately 60% of all free thiols were 
oxidized at an N/P ratio of 6. The oxidation rate decreased with rising N/P ratios, 
reaching the lowest rate for plain oligomer. Presumably the presence of siRNA 
accelerates disulfide formation because the nucleic acid acts as a template, bringing 
the positively charged oligomer molecules together into close distance [135]. 
The necessity of cysteines in three-arms was demonstrated by comparison with their 
mutated alanine analogs (Figure 19); the exchange of cysteines by alanines prevents 
stabilization of the polyplexes by disulfide crosslinking and results in loss of gene 
silencing (Figure 19A). The gel shift assay reveals that in contrast to 386, the alanine 
mutant 387 is not able to bind siRNA even at high N/P ratios (Figure 19B), making 
cellular delivery of nucleic acid impossible. 
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Figure 19: A) Gene silencing efficiency of three-armed structure 386 and its alanine analog 387 in 
Neuro2A-eGFPLuc cells with eGFP-targeted siRNA or control siRNA (at different N/P ratios). Positive 
control: succinylated PEI (sPEI). Black: GFP-siRNA, white: control-siRNA. B) Agarose gel shift at 
different N/P ratios. Ctrl: free siRNA. 
 
Similar requirements are demonstrated for the i-shape topology (Figure 20A); the 
cysteine containing i-shape oligomer 230, C-Gtp-Gtt-Stp-C-K-LinA2, showed efficient 
gene silencing, whereas the alanine analog 379 lost activity. 
Differently from the three-armed structures, the fatty acid containing i-shape oligomer 
is able to bind siRNA independent of cysteines (Figure 20B). An explanation for the 
the absence of gene silencing activity of the alanine mutant is given by Figure 20C 
and D: the cellular uptake study shows that far less labeled siRNA reaches the 
cytosol when complexed with the cysteine free version of the oligomer than with 
polymer 230. Size measurements indicate that only the i-shape with cysteines leads 
to the formation of nanoparticles with homogenous size distribution of around 100 
nm. The polyplex size of alanine analog polyplexes cannot be determined by 
Dynamic Light Scattering due to inhomogeneous and incomplete particle formation. 
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Figure 20: A) Gene silencing efficiency of i-shape structure 230 and its alanine analog 379 in 
Neuro2A-eGFPLuc cells with eGFP-targeted siRNA or control siRNA (at different N/P ratios). Positive 
control: succinylated PEI (sPEI). Black: GFP-siRNA, white: control-siRNA. B) Agarose gel shift at 
different N/P ratios. Ctrl: free siRNA. C) Cellular internalization study using flow cytometry. Cellular 
uptake of Cy5 labeled siRNA, complexed with i-shape 230 and its alanine analog 379, was determined 
via flow cytometry analysis 4 hours after transfection. D) Size and Zeta potential of siRNA polyplexes 
with i-shape oligomer 230 and its alanine analog 379, respectively, at an N/P ratio of 12; n.d. = not 
detectable. 
 
Another way of testing the necessity of cysteines is the chemical blockade of the 
thiols (Figure 21A). For this reason T-shape 49 was reacted with N-ethylmaleimide 
(NEM), irreversibly blocking the thiol groups by thioether formation. The NEM-
blocked version of the oligomer completely lost gene silencing efficiency (Figure 
21B). 
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Figure 21: A) Reaction scheme NEM blockade of T-shape 49, C-Stp-Stp-K(K-OleA2)Stp-Stp-C. B) 
Gene silencing ability of T-shape oligomer 49 w/o or with NEM blockade in Neuro2A-eGFPLuc cells 
with eGFP-targeted siRNA or control siRNA (at different N/P ratios). Positive control: succinylated PEI 
(sPEI). Black: GFP-siRNA, white: control-siRNA. 
 
In contrast, for U-shape oligomers gene silencing efficiency does not depend on 
disulfide formation in the polyplexes (Figure 22A). This can be explained by the 
strongly lipophilic character of these oligomers, which carry four fatty acids per 
molecule.  
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Figure 22: A) Gene silencing efficiency of U-shape 278 and its alanine analog 279 in Neuro2A-
eGFPLuc cells with eGFP-targeted siRNA or control siRNA (at different N/P ratios). Positive control: 
succinylated PEI (sPEI). Black: GFP-siRNA, white: control-siRNA. B) Agarose gel shift at different N/P 
ratios. Ctrl: free siRNA. 
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These hydrophobic modifications enable sufficient particle stabilization for siRNA 
delivery. The gel shift experiment (Figure 22B) illustrates the very efficient nucleic 
acid binding of both versions of the oligomer and Table 4 shows the formation of 
nanoparticles in both cases, both essential requirements for successful siRNA 
transfection. 
 
Table 4: Size and Zeta potential of siRNA polyplexes with U-shape oligomer 278 and its alanine 
analog 279, respectively, at an N/P ratio of 12. 
Polymer N/P Size [nm] Zeta potential [mV]
278 12 248 ± 26 25.2 ± 1.2
279 12 128 ± 1 17.1 ± 0.3
 
 
3.2.6 Impact of the various oligomer topologies 
Molecular topology of the oligomers seems to play a minor role in delivery efficiency 
compared to the effect of incorporating different building blocks, lipid moieties or 
cysteines. 
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Figure 23: Comparison of gene silencing ability of T-shape, i-shape and U-shape oligomers with the 
same building blocks and hydrophilic/lipophilic structure in Neuro2A-eGFPLuc cells with eGFP-
targeted siRNA or control siRNA 200 nM, at different N/P ratios. T-shapes: C-Stp-Stp-(FatA)2K]K-Stp-
Stp-C, i-shapes: (FatA)2K-C-Stp-Stp-Stp-Stp-C, U-shapes: C-(FatA)2K]K-Stp-Stp-Stp-Stp-K-Stp-Stp-
Results                                                                                            
 
 
53 
Stp-Stp-(FatA)2K]K-C. Positive control: succinylated PEI (sPEI). Black: GFP-siRNA, white: control-
siRNA. 
 
These findings were obtained by comparing the transfection efficiency of i-shape and 
T-shape oligomers with four Stp units and identical lipid moieties with U-shape 
oligomers with eight Stp units and the same lipid moieties, where no significant 
difference in transfection efficiency was detectable (Figure 23 and 24). Eight Stp 
units in the U-shape oligomers were necessary for this comparison in order to keep 
the hydrophilic/lipophilic balance the same as with the i- and T-shapes (two fatty 
acids per oligomer), as the U-shapes contain four fatty acids per oligomer. 
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Figure 24: Gene silencing ability of T-shape 463, C-Stp2-K-(K-LinA2)-Stp2-C, i-shape 471, C-Stp4-C-
K-LinA2 and U-shape 489, C-(LinA)2K]K-Stp-Stp-Stp-Stp-K-Stp-Stp-Stp-Stp-(LinA)2K]K-C, in 
Neuro2A-eGFPLuc cells with eGFP-targeted siRNA or control siRNA at decreasing siRNA 
concentrations. 
 
3.2.7 Cellular uptake of fluorescently labeled polyplexes 
The actual delivery and uptake of polyplexes into cells can be proven by fluorescently 
labeling of oligomer, siRNA or both.  In order to prove delivery capability of the novel 
structures, i-shape 229, C-Stp3-C-K-LinA2, which had already shown efficient reporter 
gene silencing in Neuro2A-eGFPLuc cells, was labeled with the fluorescent marker 
carboxyfluorescein and formulated with siRNA that was labeled with Cy5 dye. 
Microscopic pictures at according wavelengths of the fluorescent markers were taken 
24 hours after transfection (Figure 25). 
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Figure 25: Delivery of fluorescently labeled polyplexes of 229 (N/P 12) in Neuro2A cells 24 hours after 
transfection. Blue: cell nuclei stained with Hoechst 33342. A) Red: Cy5-labeled siRNA. B) Green: 
Carboxyfluorescein-labeled 229. C) Overlay picture of siRNA and oligomer. 
 
Figure 25A and B clearly show that both siRNA and oligomer have accumulated in 
the cytosol of Neuro2A cells. The overlay picture of both channels shows that most of 
the siRNA is still sticking to oligomer. The most likely reason for this is that only the 
spots with concentrated siRNA and oligomer are visible in the presented microscopic 
picture, in this case probably endo-/lysosomes, and free siRNA in the cytosol is not 
detectable in this setting because it is too diluted. The results of the previously 
mentioned luciferase reporter gene assay show that siRNA was set free into the 
cytosol, leading to specific gene silencing. 
 
3.2.8 Delivery efficacy with decreasing siRNA dosages 
So far, the screening of the oligomer library was performed with 500 ng siRNA / well 
(370 nM). Three promising oligomers were also tested with decreasing siRNA 
concentrations (Figure 26). 
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Figure 26: Dose-dependent gene silencing ability of selected transfection oligomers at constant 
oligomer concentrations. A) Gene silencing ability of i-shape 229, C-Stp3-C-K-LinA2 (3.5µg/well), U-
shape 278, C-K-(K-(LinA)2)-Stp3-K-(K-(LinA)2)-C (4.7µg/well), and T-shape 49, C-Stp2-K-(K-OleA2)-
Stp2-C (3.1µg/well), in Neuro2A-eGFPLuc cells with eGFP-targeted siRNA at decreasing siRNA 
concentrations. B) Analogous experiment using control siRNA. 
 
For example, i-shape oligomer 229 and U-shape oligomer 278 achieved a 
knockdown of approximately 50% with an siRNA concentration of 30 nM without 
unspecific effects on the cells. 
 
3.2.9 Gene silencing efficiency on different cell lines 
All synthesized oligomers were originally screened on the murine neuroblastoma cell 
line N2A, stably transfected with the eGFPLuc reporter gene, for their gene silencing 
efficiency. In figure 27, the efficiency of the oligomers was examined on a broader 
scale. One oligomer of each topology class, which had successfully delivered siRNA 
in N2A cells, was tested on a variety of other cell lines (human prostate carcinoma 
DU-145, human hepatoma HUH-7, human hepatoma HepG2 and human cervix 
carcinoma KB cells). 
Especially the lipopolymers i-shape 229 and U-shape 278 showed high transfection 
efficiency on a broad range of cell lines, occasionally with some unspecific gene 
silencing at high N/P ratios. Treatment of HUH-7 hepatoma cells with these 
oligomers resulted in activation of cell metabolism, indicated by the induction of 
luciferase expression in the control-siRNA group far above that of buffer treated 
control cells. Despite this induction, a clear difference in reporter gene expression 
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between GFP-siRNA treated and control-siRNA treated cells could be observed, 
showing successful siRNA delivery. 
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Figure 27: Gene silencing ability of selected oligomers of the four major molecular shapes in various 
cell lines, all stably transfected with the eGFPLuc fusion protein. A) Neuro2A murine neuroblastoma 
cells. B) DU-145 human prostate carcinoma cells. C) HUH-7 human hepatoma cells. D) HepG2 
human hepatoma cells. E) KB human cervix carcinoma cells. Positive control: succinylated PEI (sPEI). 
Black: GFP-siRNA, white: control-siRNA. Oligomer sequences: 49 C-Stp-Stp-K(K-OleA2)Stp-Stp-C, 
229 (LinA)2K-C-Stp-Stp-Stp-C, 386 (C-Stp-Stp-Stp)2]K-Stp-Stp-Stp-C, 278 C-(LinA)2K]K-Stp-Stp-Stp-
(LinA)2K]K-C. 
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T-shape 49 was especially successful in prostate carcinoma DU-145 cells, whereas 
the three-armed 386 only achieved moderate specific gene silencing in other cell 
lines apart from N2A. These findings show that from the synthesized catalog of 
oligomers, there is an appropriate delivery agent available for each tested cell type, 
but there is no universal carrier suitable for all cell lines. In every individual case, the 
most effective structure has to be detected experimentally. 
 
3.2.10 Cytotoxicity of plain oligomer 
Selected oligomers, which were effective in siRNA delivery, were tested for their 
cytotoxic impact on Neuro2A cells. Therefore, the cells were treated with serial 
dilutions of i-shape 230, three-arm 386 or U-shape 278. The effect on cell viability 
was compared to that of buffer treated control cells. The well characterized polymer 
linear PEI was chosen for comparison of the new carriers with established structures 
(Figure 28). 
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Figure 28: Toxicity of oligomers on Neuro2A-eGFPLuc cells 48 hours after oligomer addition in 
comparison to linear polyethylenimine (linPEI, 22 kDa). 
 
Results show that linPEI leads to cell death at concentrations of 2 µg/well, whereas i-
shape 230 has the same toxic effect only at a tenfold higher dose. The three-arm 386 
only shows very moderate toxicity even at the highest tested dose of 20 µg oligomer / 
well and U-shape 278 does not show any toxic effect at all tested concentrations. 
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Taken together the results demonstrate a dramatic decrease of cytotoxicity 
compared to the widely used standard polymer linear PEI. 
 
3.2.11 Polyplex serum stability 
Stability of polyplexes in the blood stream is essential for successful systemic 
delivery of siRNA in vivo. Interactions with blood components, especially electrolytes 
or proteins like the negatively charged albumine, can lead to dissociation or 
aggregation of administered polyplexes. In order to determine the stability, an 
agarose gel shift assay was performed with the polyplexes of selected oligomers. 
Prior to the loading of the gel, the formed polyplexes were incubated with increasing 
concentrations of fetal bovine serum, thereby imitating in vivo conditions (Figure 29). 
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Figure 29: siRNA polyplex stability in serum determined by agarose gel shift assay at N/P 12 and 
indicated FBS serum concentrations. Serum was added to the polyplexes after particle formation and 
the samples were incubated for 15 minutes at ambient temperature. As in all experiments, chemically 
stabilized siRNA was used. 
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The polyplexes of lipophilic U-shape oligomers 278 and 279 in particular showed 
sustained stability under these conditions. Some moderate siRNA release could be 
observed for all oligomers at the highest possible FBS concentration in this assay 
(90%), especially for three-armed oligomer 386. 
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3.3 Functionalized and targeted siRNA delivery systems 
3.3.1 Folate-PEG-siRNA conjugate for receptor mediated siRNA uptake 
3.3.1.1 Design of folate receptor targeted siRNA 
Receptor targeted delivery of polyplexes by incorporation of targeting ligands into the 
carrier system enables specific uptake and accumulation of the nanoparticles in the 
desired tissue. In this case, the targeting ligand folic acid was not linked to a carrier 
but directly to the payload, the siRNA (Scheme 4). 
 
Scheme 4: Folate-PEG-siRNA conjugate. The targeting ligand is linked to the siRNA via PEG spacer 
(24 ethylene glycol units) and a reducible disulfide bond. 
 
 
Incorporation of the longest available defined PEG spacer between nucleic acid and 
targeting ligand, consisting of 24 ethylene glycol units, should ensure the 
presentation of the targeting ligand on the surface of the resulting poylplexes and at 
the same time reduce the surface charge of the particles for reduced unspecific 
interactions with blood components or normal tissue in case of systemic application. 
The PEGylated targeting ligand was synthesized by solid phase peptide synthesis 
and the siRNA conjugate was purified to maintain a high degree of purity (synthesis 
by C. Dohmen, see [136]). This way, reliable conclusions about structure-activity 
relationships can de drawn from the combination of the siRNA conjugate with the 
monodisperse carriers like the three-armed oligomer 386. 
 
3.3.1.2 Determination of folate receptors on KB cells 
For clear examination of the folate-PEG-siRNA conjugate, a cell line is required 
which expresses the targeted receptor, in this case the human folic acid receptor 
(FOLR-1). The KB cell line, established by HeLa cell contamination, has been 
reported to highly express this specific receptor [137, 138]. For confirmation of the 
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receptor status, cells were examined via antibody staining with anti-human FOLR-1 
antibody (Figure 30). 
 
A) B)
 
Figure 30: Folate receptor staining with human FOLR-1 antibody conjugated to Allophycocyanin (red). 
A) Human cervix carcinoma KB cells. B) Human hepatoma HUH-7 cells as control. Blue: cell nuclei 
stained with Hoechst 33342 dye. 
The microscopic images after antibody staining show that the KB cells express 
FOLR-1 on the cell surface, whereas no signal is observable on the surface of the 
control cell line HUH-7. Thus, the purchased KB cell line is suitable for investigation 
of folic acid receptor targeted siRNA delivery. 
 
3.3.1.3 Uptake of plain FA-PEG-siRNA into folate receptor expressing cells 
After confirmation of the high folic acid receptor expression on the surface of KB 
cells, the folate-PEG-siRNA conjugate (FA-PEG-siRNA) was applied to the cells and 
receptor mediated uptake of the conjugate was monitored. After 16 hours of 
incubation, the microscopic images showed that an immense amount of fluorescently 
labeled conjugate had been taken up into KB cells, but addition of lysotracker green 
revealed that all of the siRNA was trapped in endo-/lysosomes, where it is degraded 
and cannot take action by incorporation into the cytosolic silencing complex of the 
RNAi machinery (Figure 31A and B). Control experiments proved that the uptake 
took place in a receptor mediated fashion, as internalization in KB cells could be 
completely blocked by preincubation with an excess of free folate or treatment with 
untargeted PEG-siRNA (Figure 31C and D). 
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A) B)
C) D)
 
Figure 31: Cellular uptake of FA-PEG-siRNA in human cervix carcinoma KB cells (siRNA 
concentration: 370 nM). A) FA-PEG-siRNA treated KB cells. B) Overlay of A) with additional channel 
of lysotracker
©
 green for staining of endo-/lysosomes (overlay of red and green channel causes yellow 
color). C) FA-PEG-siRNA treated KB cells after preincubation with an excess of folate. D) PEG-siRNA 
treated KB cells. Blue: Hoechst 33342, red: Cy5 labeled siRNA, green: lysotracker
©
 green. 
 
These findings were underlined by flow cytometry experiments (Figure 32). Again, a 
strong uptake into KB cells was detected for the FA-PEG-siRNA conjugate, whereas 
competition with an excess of free folic acid or treatment with untargeted PEG-siRNA 
only showed a minor shift in fluorescence intensity compared to buffer treated 
control. Additionally, a control experiment with Neuro2A cells with low folic acid 
receptor expression was performed, in which only marginal uptake of the FA-PEG-
siRNA conjugate was detectable, supporting the receptor specificity of internalization. 
The internalization studies showed that the ligation of folic acid to siRNA via PEG 
spacer led to efficient receptor mediated uptake of the conjugate into folic acid 
receptor expressing cells. However, the entrapment in endosomes and the small size 
of these molecules, which would cause rapid clearance from blood circulation in vivo, 
make formulation with a carrier system, e.g. polymers with endosomal escape 
functionalities, indispensable for successful cytosolic delivery of the nucleic acid and 
effective gene silencing. 
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Figure 32: Cellular internalization study using flow cytometry. Cellular uptake of Cy5 labeled FA-PEG-
siRNA was determined via flow cytometry analysis (“+ FA comp.” = preincubation of cells with an 
excess of folate). A) KB cells. B) Folic acid receptor negative Neuro2A cells. 
 
3.3.1.4 Proof of functionality of folate receptor targeted siRNA in a non-
targeted setting 
Functionality of siRNA is often affected by modification of the double strand due to 
insufficient cleavage of the double helix before integration into the silencing complex 
or imperfect incorporation of the antisense strand into the RISC. 
 
25 6 12 6 12 6 12
0%
20%
40%
60%
80%
100%
GFP-siRNA control-siRNA
sPEI siRNA FA-siRNA PEG-siRNA
N
/Plu
c
ife
ra
s
e
 e
x
p
re
s
s
io
n
 (
%
 o
f 
c
o
n
tr
o
l)
 
Figure 33: Gene silencing ability of modified (FA-PEG-siRNA and PEG-siRNA) versus unmodified 
siRNA complexed with oligomer 230, C-Gtp-Gtt-Stp-C-K-LinA2, in Neuro2A-eGFPLuc cells (N/P 12 
and 20). No medium change was performed after transfection with an incubation time of 48 hours. 
Positive control: succinylated PEI (sPEI). Black: GFP-siRNA, white: control-siRNA. 
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Although modification with PEG and targeting ligand took place at the 5′ end of the 
sense strand, functionality of the modified siRNA was confirmed by comparing the 
silencing efficiency of the FA-PEG-siRNA conjugate to PEG-siRNA and unmodified 
siRNA in a non-targeted reporter gene assay. For this purpose, the three different 
siRNA batches were individually complexed with the lipophilic oligomer 230 and 
Neuro2A-eGFPLuc cells were transfected with the resulting polyplexes for 48 hours 
(Figure 33). Both PEG-siRNA and FA-PEG-siRNA showed equal silencing ability to 
unmodified siRNA, affirming that the strand modification had no impact on the 
functionality of the siRNA inside the cell. 
 
3.3.1.5 Formulation of folate receptor targeted siRNA with three-armed 
oligomer 386 
The lipophilic oligomer 230 successfully delivered the targeted siRNA conjugate into 
the cytosol of cells in a non-targeted transfection setting. For folate receptor targeted 
delivery this oligomer proved inadequate because of its lipophilic tails, leading to 
micellar structures of the resulting polyplexes and thus masking the targeting ligand 
of the siRNA conjugate. In consequence, the masking of the targeting ligand led to 
undesired unspecific cellular uptake (data not shown). 
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Figure 34: A) Gel shift assay of modified and unmodified siRNA, complexed with three-armed polymer 
386 (N/P 6 and 12). Ctrl: free siRNA. B) Size and Zeta potential of the corresponding polyplexes. 
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Three-armed 386, another carrier from the previously mentioned oligomer library, 
possesses more favourable characteristics. The strongly hydrophilic structure, free of 
lipid moieties, bears a terminal cysteine in each arm for crosslinking during polyplex 
formation and gene silencing ability of this oligomer has already been shown in 
Neuro2A-eGFPLuc cells in a non-targeted fashion (Figure 19A). Thus, FA-PEG-
siRNA was complexed with 386 and siRNA binding ability, particle size as well as 
Zeta potential was determined for the formed polyplexes. 
The gel electrophoresis assay showed stable particle formation for the oligomer with 
the targeted siRNA conjugate (Figure 34A). Particle size of the polyplexes with 
PEGylated siRNA increased, but the decrease of the Zeta potential for the 
PEGylated particles in comparison to polyplexes with unmodified siRNA confirmed 
that the PEG moiety with the targeting ligand attached is present on the surface of 
the polyplexes (Figure 34B). 
Receptor mediated uptake of the targeted polyplexes was determined via flow 
cytometry (Figure 35). 
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Figure 35: Flow cytometric analysis of cellular uptake of polyplexes formed with Cy5 labeled siRNA 
conjugates and oligomer 386. Uptake of FA-PEG-siRNA polyplexes was tested with or w/o 
preincubation of cells with an excess of folate. A) N/P 6. B) N/P 12. 
 
A more than tenfold increased cellular uptake was detected for polyplexes containing 
the FA-PEG-siRNA conjugate compared to particles with PEG-siRNA. In addition, the 
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reduced cellular internalization of folic acid receptor targeted polyplexes in the 
presence of excess folic acid confirmed the receptor specific endocytosis pathway. 
Some unspecific internalization in this assay, shown by an uptake of untargeted 
PEG-siRNA polyplexes, can be explained by the incomplete shielding of the 
polyplexes by PEGylation of the siRNA. This was indicated by a reduced but still 
positive Zeta potential of the PEGylated particles. Hence, ionic interactions between 
the positively charged polyplex with the negatively charged cell surface are not 
completely abrogated, leading to minor unspecific internalization. 
After having increased the size of the FA-PEG-siRNA, the major limitation of this 
conjugate, which should be solved by formulation with a carrier system, was 
examined: the entrapment in endosomes. For this reason different mixtures of FA-
PEG-siRNA with plain siRNA were complexed with 386 and tested in a luciferase 
reporter gene assay (Figure 36). 
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Figure 36: Gene silencing activity of polyplexes with different mixtures of targeted and nontargeted 
siRNA (% of targeted siRNA in total siRNA), complexed with three-armed polymer 386 (N/P of 6) in 
folate receptor positive, human cervix carcinoma KB-eGFPLuc cells. Medium change after 30 minutes. 
Final siRNA concentration: 200 nM. Black: GFP-siRNA, white: control-siRNA. 
 
Polyplexes containing only 2.5% targeted siRNA of total siRNA and higher were able 
to successfully mediate gene silencing in a receptor targeted fashion. Proof for the 
receptor specific manner is provided by the lack of gene silencing efficiency for PEG-
siRNA polyplexes in all ratios. As RNAi takes place in the cellular cytosol, this assay 
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gives evidence for successful endosomal escape of the targeted siRNA. Remarkably, 
the complexes have no impact on the viability of the treated cells, indicated by the 
absence of knockdown in the control-siRNA treated cells. 
The reporter gene assay in figure 36 was performed with a final siRNA concentration 
of 200 nM. Because high potency is an important factor for successful and repeated 
application of new entities, the gene silencing ability of the presented system was 
tested with decreasing siRNA dosages at a fixed level of oligomer concentration 
(Figure 37). 
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Figure 37: Gene silencing efficiency of targeted polyplexes with decreasing siRNA dosages in KB-
eGFPLuc cells. Polyplexes were formed using constant amounts of polymer 386 (0.53 μg) and (in the 
highest concentration) 135 ng siRNA (final concentration 100 nM) or stepwise reduced siRNA 
amounts (final concentrations 50 nM, 25 nM, or 12.5 nM). For each siRNA concentration, indicated 
mixtures of targeted and non-targeted siRNA were applied (label of x-axis refers to the % of targeted 
siRNA of total siRNA). Medium change after 30 minutes. 
 
Results                                                                                            
 
 
68 
As demonstrated, high transfection efficiency was conserved down to siRNA 
concentrations of 25 nM. At these low doses, a higher amount of targeted siRNA was 
necessary to achieve equal levels of gene silencing as with higher siRNA 
concentrations. Decrease of efficiency was observed at 12.5 nM siRNA. 
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3.3.2 Influenza peptide – siRNA conjugate (INF-siRNA) 
3.3.2.1 Design of the influenza peptide – siRNA conjugate 
The lytic peptide INF7, an acidic modified version of the 23 amino-terminal amino 
acid sequence of the influenza virus hemagglutinin subunit HA-2, has proven pH 
specific lytic activity by switching to an alpha-helical conformation at endosomal pH 
[139]. Incorporation of components with pH specific membrane activity into 
polyplexes facilitates the rupture of endosomes after acidification and thereby 
improves transfection efficiency of the polyplexes after endocytosis. The overall 
negative charge of INF7 makes it an ideal candidate to be directly linked to siRNA, as 
this modification does not reduce the binding between cationic polymer and nucleic 
acid by electrostatic interaction (Scheme 5). 
 
Scheme 5: INF-siRNA. The lytic peptide INF7 is linked to siRNA by a reducible disulfide bond. 
 
 
As attachment site, again the 5’ end of the sense strand was chosen for minimizing a 
potential impact on the silencing efficiency of the siRNA. The linkage between 
peptide and nucleic acid contains a reducible disulfide bond, which can be cleaved in 
the reductive environment of the cytosol. The conjugate was purified, resulting in a 
defined structure (synthesis by C. Dohmen, see Diss. Dohmen 2012). 
 
3.3.2.2 Formulation of INF-siRNA with sequence defined oligomers for 
enhanced endosomal release and efficient gene silencing 
For some oligomers of the discussed library, effective siRNA delivery could be 
detected but gene silencing efficiency of the polyplexes was insufficient. Reason for 
this might be the missing endosomal escape ability of these particular oligomers. The 
microscopic images in figure 38 show an example where this is the case. Oligomer 
76, C-Stp-(OleA)2K]K-Stp-C, forms stable particles with regular siRNA, which are 
readily internalized into cells (Figure 38A) but remain stuck in endosomes (Figure 
38B), where they face degradation in the endo-/lysosomal process. 
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A) B)
 
Figure 38: Cellular uptake of fluorescently labeled siRNA complexed with oligomer 76 in HUH7 cells. 
A) Cy5 labeled siRNA in endosomes. B) overlay of siRNA channel with lysotracker green channel. 
Blue: cell nuclei (Hoechst 33342), red: siRNA; green: Lysotracker green, yellow: fusion of red and 
green. 
 
This carrier system presents the perfect test object for the activity of INF-siRNA. The 
membrane disruptive character of INF-siRNA at pH 5 should facilitate endosomal 
release of the internalized polyplexes and enable siRNA mediated gene knockdown. 
Efficiency of the combination of oligomer 76 and INF-siRNA is presented in Figure 
39. 
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Figure 39: Gene silencing efficiency of oligomer 76 complexed with regular siRNA or INF-siRNA in 
Neuro2A-eGFPLuc cells at different N/P ratios. Positive control: succinylated PEI (sPEI). Black: GFP-
siRNA, white: control-siRNA. 
 
Compared to regular siRNA, the influenza peptide modified siRNA achieves potent 
silencing of the luciferase signal at low N/P ratios of oligomer 76, with moderate 
impact on cell viability, demonstrated by the minor decrease of protein expression in 
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the control-siRNA treated cells. This experiment shows the lytic potential of the INF-
siRNA conjugate at endosomal pH and its ability to grant gene silencing ability to 
otherwise unfeasible carriers. 
Another example for successful restoration of transfection efficiency is shown in 
figure 40.  
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Figure 40: Gene silencing efficiency of three-armed oligomer 386 complexed with regular siRNA or 
INF-siRNA in KB-eGFPLuc cells at different N/P ratios. Positive control: succinylated PEI (sPEI). 
Black: GFP-siRNA, white: control-siRNA. 
 
Three-armed oligomer 386, which demonstrated high gene silencing in murine 
neuroblastoma Neuro2A-eGFPLuc cells, only had a very moderate effect in the 
human cervix carcinoma KB cell line (Figure 40). With the help of INF-siRNA, 
luciferase expression was reduced below 20% at low cytotoxicity levels. Obviously, 
the polyplexes lacked endosomal escape activity in KB cells, possibly because of 
variations in endosomal acidification in the different cell lines, reducing endosomal 
swelling through the proton sponge effect of the oligomer by its buffering capacity. 
 
3.3.2.3 Comparison of INF-siRNA conjugates coupled by disulfide or 
maleimido linkage 
In the described INF-siRNA conjugate the linkage between nucleic acid and influenza 
peptide contains a disulfide bond for cleavage in the reductive environment of the 
cytosol after endosomal escape, so the siRNA retains its full functionality. The 
necessity of this reversible linkage was explored by comparison of the conjugate with 
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its non-degradable counterpart INF-Mal-siRNA, where the two components are 
coupled via a maleimide linker. 
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Figure 41: Gene silencing efficiency of oligomer 356 complexed with INF-SS-siGFP or INF-Mal-siGFP 
in KB-eGFPLuc cells at different N/P ratios. Medium change after 30 minutes. 
 
When complexed with oligomer 356 (see below), a clear reduction of knockdown 
efficiency is observable for the non-cleavable conjugate (Figure 41), demonstrating 
the necessity of the reducible disulfide linkage within the construct. Although the lytic 
peptide is coupled to the 5’ end of the sense strand, the modification seems to hinder 
the incorporation of the antisense strand into the RNAi machinery. 
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3.3.3 Multifunctional, folate receptor targeted carrier system for receptor 
mediated uptake of lytic INF-siRNA 
3.3.3.1 Design of the folate receptor targeted, pegylated oligomer 
The previous work has described functionalization of siRNA either with targeting 
ligand or lytic peptide for improved delivery capabilities of siRNA carriers, based on 
oligo (ethane amino) amides. A combination of both functionalities should have 
synergistic effects on transfection efficiency of polyplexes. In addition, shielding, e.g. 
by incorporation of polyethylene glycol (PEG) into the system, can prevent interaction 
with blood components and thereby prolong circulation half life of nanoparticles in the 
blood stream. A simple mixture of both siRNA conjugates, in combination with upper 
mentioned oligomers, did not result in enhanced, targeted gene silencing (data not 
shown). The present study combines the targeting and shielding function of the new 
oligomer 356, also synthesized by solid phase peptide synthesis, with the lytic activity 
of the characterized INF-siRNA conjugate (Scheme 6; synthesis by C. Dohmen, see 
Diss. Dohmen 2012). 
 
Scheme 6: Functionalized oligomer 356 with eight cationic Stp units as oligomer backbone, two 
terminal cysteines (Cys), a PEG spacer consisting of 24 ethylene oxide monomers inserted in the 
middle of the backbone by coupling to lysine (Lys) and the targeting ligand folic acid at the end of the 
PEG chain. 
 
 
The oligomer backbone consists of eight Stp building blocks with a terminal cysteine 
at each end of the chain for crosslinking during polyplex formation. In the middle of 
the backbone, a PEG chain, consisting of 24 ethylene glycol units (PEG24), is 
incorporated, with folic acid attached to its distal end for targeting of the human folic 
acid receptor (FOLR-1). The construct combines siRNA binding with shielding and 
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targeting functionalities. For efficient endosomal escape, the lytic activity of INF-
siRNA was exploited, as previous studies with the Stp-oligomer 386 showed that 
polyplexes with unmodified siRNA are not able to mediate efficient gene silencing in 
folic acid receptor positive KB cells, due to insufficient endosomal escape (Figure 
36). 
 
3.3.3.2 Cellular association of targeted carrier system on folate receptor 
positive cells 
The first step in targeted siRNA delivery is the successful binding of the polyplexes to 
the targeted receptor, in this case the folic acid receptor. Cellular association of 
polyplexes, consisting of fluorescently labeled INF-siRNA, complexed with the new 
construct 356, C-Stp4-K(Stp4-C)-PEG24-FA, was determined by flow cytometry. 
Cells were incubated with the polyplexes for 30 minutes on ice in order to minimize 
cellular uptake. Receptor specific attachment to the cell surface was examined in 
control samples by competition of receptor binding by preincubation of the cells with 
an excess of free folic acid (Figure 42). 
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Figure 42: Cellular association assay of fluorescently labeled (Cy5)-INF-siRNA (200 nM) complexed 
with 356, C-Stp4-K(Stp4-C)-PEG24-FA, on KB cells. Incubation was performed on ice and medium 
was exchanged after 30 minutes. Black: HBG control. Gray: 356 polyplexes on KB cells, preincubated 
with an excess of folate on ice for 30 minutes. Dashed: 356 polyplexes on KB cells. 
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Results showed that the polyplexes could only bind to the cell surface when the folic 
acid receptors were not blocked by an excess of free folate, demonstrating the 
receptor specific binding to KB cells. 
 
3.3.3.3 Functional groups in the folate targeted carrier system for receptor 
mediated siRNA delivery and gene silencing 
The construct 356, C-Stp4-K(Stp4-C)-PEG24-FA, carries functional groups for 
crosslinking, shielding and folic acid receptor specificity. For the determination of the 
necessity of the incorporated functional groups for successful siRNA delivery, two 
mutated versions of the construct were synthesized by solid phase peptide synthesis, 
depleting either the cysteines or the targeting ligand. This way, clear structure-activity 
relationships of the carrier system can be determined. In structure 420, S-Stp4-
K(Stp4-S)-PEG24-FA, the two cysteines were replaced by serines, hindering thiol 
crosslinking during polyplex formation. Sequence 188, A-PEG24-K-(Stp4-C)2, lacks 
the targeting ligand folic acid, which makes receptor specific uptake impossible. The 
extent of cellular uptake of siRNA mediated by the serine and alanine analog of 356 
was monitored by flow cytometry and confocal microscope (Figure 43 and 44). 
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Figure 43: Cellular internalization assay of fluorescently labeled (Cy5)-INF-siRNA (200 nM) 
complexed with 356, C-Stp4-K(Stp4-C)-PEG24-FA, and its mutated forms. A) KB cells. I. (dark gray): 
HBG control. II. (light gray): 420, S-Stp4-K(Stp4-S)-PEG24-FA . III. (dashed): 188, A-PEG24-K-(Stp4-
C)2. IV. (black): 356. B) Neuro2A cells. Gray: HBG control. Black: 356. 
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The FACS experiments revealed that both analogs were not able to deliver the 
labeled siRNA into KB cells, emphasizing the importance of cysteines and targeting 
ligand within the construct. In a control experiment the cellular uptake of 356 
polyplexes was determined in Neuro2A cells with low folic acid receptor expression 
(Figure 43B). The diminished rate of uptake further proved the receptor based 
internalization mechanism. 
Identical results were obtained with the confocal microscopic images (Figure 44). Out 
of the three tested constructs, again only 356 was able to transfect KB cells with 
labeled INF-siRNA. The low folic acid receptor expressing control cell line, in this 
case HUH-7, which was chosen because of better adhesion characteristics than N2A 
cells, only showed marginal transfection with INF-siRNA, complexed with 356. 
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Figure 44: Cellular uptake of fluorescently labeled (Cy5)-INF-siRNA (200 nM) complexed with 356, C-
Stp4-K(Stp4-C)-PEG24-FA, and its mutated forms (N/P 16) using a confocal scanning fluorescence 
microscope. Final siRNA-concentration per well: 200 nM; transfection time: 30 minutes. Upper panel 
with two channels: Hoechst 33342 channel blue for staining of nuclei, Cy5 channel red; bottom panel 
with three channels: transmission light, Hoechst 33342 channel blue, Cy5 channel red. A) – C) KB 
cells; D) Folic acid receptor negative HUH-7 cells. A) 356. B) 420 (serine analog). C) 188 (alanine 
analog). D) 356. 
 
So far, successful cellular attachment and internalization of the targeted particles was 
demonstrated. Shielding of the resulting positively charged polyplexes was achieved 
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by the PEG chain: the Zeta potential of the particles was shown to be around zero 
(see Diss. Dohmen 2012). 
For the knockdown of a specific gene target by siRNA, one last hurdle has to be 
overcome inside the cells, the endosomal escape. Complexation of regular GFP-
siRNA with 356 only mediated marginal gene silencing in the luciferase reporter gene 
assay (Figure 45). 
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Figure 45: Gene silencing activity of INF-siRNA or regular siRNA (GFP-siRNA) complexed with 356, 
C-Stp4-K(Stp4-C)-PEG24-FA, and INF-siRNA complexed with the mutated analogs 420 S-Stp4-
K(Stp4-S)-PEG24-FA and 188, A-PEG24-K-(Stp4-C)2, in KB-eGFPLuc cells. Medium change after 30 
minutes. 
 
However, combination of the targeted, shielded and crosslinked construct with 
membrane disruptive INF-siRNA, directed against the eGFPLuc protein, led to strong 
silencing of luciferase signal in KB-eGFPLuc cells. Transfection with this carrier 
system was well tolerated by the cells, indicated by the unchanged protein 
expression in the control-siRNA treated samples. The absence of knockdown 
efficiency for the mutated analogs of 356, even with INF-siRNA, confirmed the 
findings of the previous cellular internalization studies. 
For the proof of specificity of receptor mediated uptake, control studies were also 
performed for the luciferase reporter gene assay (Figure 46). The effect of blocking 
the folic acid receptors on KB cells with an excess of free folate on transfection 
efficiency of 356 polyplexes and their gene silencing ability in Neuro2A cells with low 
folic acid receptor status was determined. 
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Figure 46: Gene silencing acitivity of INF-siRNA, complexed with 356, C-Stp4-K(Stp4-C)-PEG24-FA 
in KB-eGFPLuc cells, in KB-eGFPLuc cells which had been preincubated with an excess of folic acid 
(+ FA comp.) and in Neuro2A-eGFPLuc cells with low folic acid receptor level. Medium change after 
30 minutes. 
 
In both cases, luciferase expression was diminished only to a minor extent, indicating 
that particle uptake was insufficient because of the blocking or absence of folate 
receptors on the cell surface. 
 
3.3.3.4 Influence of variations of PEG chain length on gene silencing efficiency 
of the multifunctional, folate receptor targeted carrier system 
First in vivo trials with the new construct revealed that the small size of the 
polyplexes leads to rapid clearance from blood circulation through the kidneys (see 
Diss. Dohmen 2012). Therefore, an increase of size was crucial for future in vivo 
applications. This was accomplished by elongation of the PEG chain in the construct 
by coupling two or three PEG24 instead of just one (synthesis by C. Dohmen). 
Before further in vivo experiments could be conducted, gene silencing ability of such 
strongly shielded particles had to be determined, as a large extent of shielding can 
hamper endosomal escape of polyplexes, the so called PEG dilemma [140, 141]. 
Figure 47 shows that the elongation of the PEG chain has no impact on gene 
silencing efficiency of the construct, as both modifications show identical efficiency 
like the original carrier system 356. 
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Figure 47: Influence of variation of PEG chain length on gene silencing efficiency in KB-eGFPLuc 
cells. 356: C-Stp4-K(Stp4-C)-PEG24-FA, 477: C-Stp4-K(Stp4-C)-(PEG24)2-FA, 478: C-Stp4-K(Stp4-
C)-(PEG24)3-FA. Medium change after 30 minutes. 
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4 DISCUSSION 
 
4.1 Evaluation of lateral stabilization of siRNA polyplexes via DSP 
crosslinking 
Cross linking strategies have been reported to strongly enhance stability and 
efficiency in a broad range of nanoparticles [142-145]. In this work, the amine 
reactive, homobifunctional NHS-ester DSP was utilized for the in situ surface cross 
linking of siRNA polyplexes, formed with the biodegradable, pseudodendritic polymer 
HD-O. Successful reaction of crosslinking agent with the surface amines of the 
polyplexes could be shown by a decrease of the positive Zeta potential after the 
modification step (Table 1). A similar study had previously applied surface 
crosslinking for polymeric siRNA delivery but with a different linker, which is only 
reactive at alkaline pH, far higher molar ratios between crosslinker and polymer, and 
with a non degradable PAMAM dendrimer [146]. 
Opimization of the HD-O/siRNA ratio, as well as tuning of the linker/polymer ratio 
proved essential for the formation of stable, nano-sized particles. Nevertheless, the 
surface cross linking with DSP presents a simple and reproducible method for 
increasing the lateral stability of siRNA polyplexes. This was demonstrated in the 
successful delivery of siRNA directed against the luciferase reporter gene, which led 
to effective luciferase silencing in two different cell lines, stably expressing the eGFP-
luciferase fusion protein (Figure 8). Control experiments with non-coding siRNA, as 
well as measurement of the cell viability after polyplex treatment, confirmed the good 
tolerability of the stabilized particles in vitro. 
Actual intracellular delivery of siRNA by the DSP-stabilized polyplexes was proven by 
flow cytometry (Figure 10 and 11). Internalization of plain HD-O polyplexes was only 
detectable to a minor extent. This is another hint that the presented polyplexes are 
on the edge of surviving in serum and electrolyte containing medium but need just 
some improvement in stability for actually doing so. 
Replacement of the Luc-siRNA in the polyplexes by siRNA directed against the 
endogenous target AHA1 resulted in strong, specific silencing of AHA1 mRNA, again 
only for the DSP stabilized polyplexes (Figure 12). Even though a moderate 
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reduction of AHA1 mRNA was detected in samples treated with nonstabilized 
polyplexes, the analogous luciferase siRNA delivery experiments (measuring the 
actual end product of gene expression, the protein) indicate that the level is 
insufficient for the silencing. The current work presents encouraging data for future 
applications of the DSP linker strategy for stabilizing siRNA polyplexes, while 
preserving the biodegradability of the applied polymers. This stabilization strategy 
might be optimized for a future successful in vivo application of such siRNA 
polyplexes. 
 
 
4.2 Evaluation of solid phase derived, sequence-defined siRNA 
carriers based on oligo (ethane amino) amides 
For a systematic optimization of polymeric carriers for siRNA delivery, we chose a 
strategy based on solid phase supported synthesis which allows the generation of 
precise sequence-defined oligomer structures [122, 126, 127]. In this study a small 
library of 39 solid phase derived oligomers assembled into four different topologies 
using four different novel oligo (ethane amino) building blocks, six different fatty acids 
and/or cysteines, were examined for their ability to form siRNA polyplexes and 
mediate gene silencing. 
Initially, four different artificial oligoamino acids building blocks (Stp, Gtp, Ptp, Gtt; 
see [126] and Scheme 2) were screened in two oligomer topologies (i-shapes, three-
arms). These building blocks contain the same proton-sponge 1,2-diaminoethane 
motif as present in polyethylenimine and analogous efficient polymeric nucleic acid 
carriers [39, 74, 147, 148]. siRNA binding and gene silencing studies (Figure 13) 
revealed that only the three tetraethylenpentamine (tp) containing building blocks, but 
not the triethylentetramine (tt) containing building block (Gtt), have promising 
properties as oligomer backbone units. Stp, succinamidyl-tetraethylenpentamine, 
displayed the greatest potential amongst the new artificial amino acids. The glutaric 
acid-containing Gtp and phthalic acid-containing Ptp building blocks displayed 
weaker siRNA binding ability than Stp but still have effective gene silencing efficiency 
when incorporated into the i-shape topology. In contrast, Gtt with only two protonable 
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nitrogens per repeating unit results in oligomers with lowest siRNA binding ability and 
thus appears not as useful for assembly of siRNA carriers. 
Within the investigated classes of oligomers, polyplex stability appears as an 
important parameter. Stability appears as even more critical for siRNA as compared 
with plasmid DNA polyplexes [127, 129]. Therefore functional modifications were 
incorporated into oligomers to stabilize polyplexes: cysteines, which after siRNA 
complexation provide covalent stabilizing crosslinks within the formed nanoparticle, 
and/or lipophilic α,-diacyl-modified lysines which provide nanoparticle stabilization 
by non-covalent hydrophobic interactions (see below). 
Systematic variation of the chain length of Stp units in carriers with three-arm, T-
shape and U-shape topology (Figure 17) revealed that small, hydrophilic oligomers 
with only one Stp unit per arm are incapable of mediating gene silencing, despite the 
incorporation of stabilizing cysteines. Only for the lipophilic, poorly water-soluble U-
shape oligomer already one Stp unit was sufficient for siRNA delivery. More general, 
the minimum required and also sufficient repeat number was two Stp subunits per 
arm. Further elongation did not significantly enhance gene silencing activity in vitro. 
For the water-soluble oligomers with three-arm, i-shape and T-shape topology, 
cysteines were essential to achieve siRNA transfection activity. Through disulfide 
crosslinks, the small oligomers form larger structures during the polyplex formation 
process, but biodegradability should be maintained by cytosolic reduction. Monitoring 
of the disulfide formation process during polyplex formation with a three-armed 
structure revealed that the crosslinking reaction is accelerated in the presence of 
siRNA, which most probably acts as a template in the process (Figure 18). The 
requirement of disulfide formation was demonstrated either by blocking the cysteine 
mercapto groups with NEM (Figure 21) or by lack of activity when cysteine was 
replaced by alanine (Figures 19 and 20). For the alanine mutants of the three-armed 
structures a poor siRNA binding ability could be shown, resulting in absence of gene 
silencing efficiency (Figure 19), whereas the fatty acid containing i-shape alanine 
mutant effectively retained siRNA in the gel shift assay but also lacked gene silencing 
ability. Reason for this is most likely the insufficient particle formation, underlined by 
the reduced cellular uptake compared to their cysteine containing counterparts 
(Figure 20). The more lipophilic U-shape oligomers, carrying diacyl groups at both 
ends of the polyamine oligomer backbone, do not need cysteines for gene silencing 
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activity (Figure 22). Here the twofold hydrophobic domains lead to a strong 
hydrophobic stabilization of siRNA polyplexes, making disulfides dispensable for 
efficient siRNA binding and formation of nanosized polyplexes. 
The type of lipidic diacyl moieties incorporated into the oligomers were analyzed in 
detail, screening saturated fatty acids from C4 to C18 and two unsaturated C18 fatty 
acids. Incorporation of the two unsaturated C18 fatty acids, oleic and linolic acid, 
resulted in pH specific membrane lysis behavior and most effective gene silencing, 
both in the case of T-shapes (Figure 15) and i-shapes (Figure 16). This positive 
effect of lipidic moieties is consistent with previous reports with polymerizable 
surfactants and lipopolymers [40, 147]. 
Within the evaluated lipid-modified Stp oligomers, the different topologies (i-shape, T-
shape, U-shape) proved to play only a minor role in the gene silencing efficiency of 
the oligomers when compared at a defined fixed ratio (2/4 or 4/8) of hydrophobic fatty 
acid / hydrophilic Stp building blocks (Figure 23 and 24). 
Proof for successful delivery of siRNA into cells with the help of the novel oligomers 
was provided by flow cytometry (Figure 20) and microscopic imaging experiments 
(Figure 25) with fluorescently labeled polyplexes, ruling out possible unspecific 
effects in the reporter gene assays. The microscopic pictures showed that signals 
from labeled oligomer and labeled siRNA could be overlaid, confirming that intact 
polyplexes were internalized into the cells. 
Efficacy of polyplexes at low siRNA dosages is especially important with regard to in 
vivo applications, as low doses are favorable for avoiding side effects and for 
repeated treatment options. For this reason three lipid modified oligomers with 
different topologies were tested for gene silencing efficiency at decreasing siRNA 
dosages. The oligomers showed activity even at low siRNA concentrations, 
highlighting the potential of the new structures (Figure 26). 
Structure-activity relationships of the new siRNA carriers were explored in the murine 
neuroblastoma cell line N2A. For a broad application, efficient delivery of nucleic 
acids in various different cell types is required. Especially the oligomers with lipidic 
moieties demonstrated efficient silencing ability in a broad range of human cancer 
cell lines (Figure 27). 
Established polymers for nucleic acid delivery, e.g. PEI [23, 149] or PAMAM [150-
152], often show significant signs of cytotoxicity at high concentrations or after 
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repeated application. Although good tolerability of the new carriers, based on oligo 
(ethane amino) amides, has already been shown in the luciferase reporter gene 
assays, where complexation with control-siRNA had no effect on luciferase protein 
expression, dose escalation studies were performed with selected oligomers for the 
evaluation of their cytotoxic potential. The data showed a tenfold reduced or even 
lower cytotoxicity for the oligomers compared to linear PEI (Figure 28), opening up 
the possibility of repeated in vivo application without causing severe side effects. 
The harsh environment in the bloodstream with electrolytes, proteins and mechanic 
stress often destroys the majority of systemically applied polyplexes. However 
extracellular stability is essential for the cytosolic delivery of siRNA at the target site. 
A serum stability assay (Figure 29), which is supposed to simulate extracellular in 
vivo conditions, demonstrated high stability for most tested structures, especially for 
the lipid modified oligomers, making them interesting candidates for in vivo 
application. 
In conclusion, the application of solid phase peptide synthesis on oligomer assembly 
enables clear insights into structure-activity relationships between the shape, 
sequence and functional modifications of oligomers and their efficiency in siRNA 
delivery. With the help of this strategy, several new promising polymer classes were 
identified for siRNA delivery. The new strategy also enables further optimization 
through precise, site-specific functionalization of the carrier systems, such as 
introduction of PEG shielding and receptor targeting domains. 
 
 
4.3 Evaluation of functionalized and targeted siRNA delivery 
systems 
4.3.1 Folate conjugated siRNA for receptor mediated siRNA uptake 
The described new class of oligomers has shown to efficiently bind siRNA, form 
stable nanoparticles and transfect cells. For successful systemic application of these 
siRNA carriers, functionalization of the resulting polyplexes is essential for specific 
uptake into the desired tissue. The folate-PEG-siRNA conjugate proved a suitable 
way for introducing a targeting ligand into the particles, enabling receptor specific 
cellular internalization. The plain siRNA conjugate was readily taken up into folic acid 
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receptor positive cells by receptor mediated endocytosis (Figure 31 and 32). 
However, reporter gene silencing could not be achieved by the plain construct due to 
insufficient endosomal escape (Figure 31). Similar findings have already been 
reported in literature [153]. Functionality of the siRNA was fully maintained after 
modification of the double strand, which was demonstrated by its delivery with a 
lipophilic transfection agent in a non-targeted setting (Figure 33). Entrapment and 
degradation of the construct in the endolysosomal compartment was circumvented 
by formulation of the FA-PEG-siRNA conjugate with three-armed oligomer 386. The 
hydrophilic PEG spacer between targeting ligand and nucleic acid within the siRNA 
construct reduced the surface charge of the polyplexes, confirming the presentation 
of the ligand on the polyplex surface, which is essential for receptor mediated 
internalization (Figure 34). Furthermore, the decrease of the Zeta potential reduces 
unspecific interactions between polyplex and cell surface, increasing the selectivity of 
cellular uptake. Receptor specific internalization of the stable particles was 
demonstrated by comparing the cellular uptake rate of functionalized FA-PEG-siRNA 
polyplexes with polyplexes of folic acid depleted PEG-siRNA, which showed a 
substantially reduced internalization rate (Figure 35). Additional proof was obtained 
by receptor competition experiments with an excess of free folic acid, in which the 
internalization rate of polyplexes with the construct were diminished. The folic acid 
receptor targeted polyplexes mediated strong gene silencing in FOLR-1 positive KB 
cells, confirming the endosomal release of siRNA, as this is a requirement for the 
activity of siRNA within the cytosolic RNAi machinery (Figure 36). Three-armed 
oligomer 386 contains 1,2-diaminoethane units, similar to polyethylenimine, which 
are responsible for the proton sponge effect in endosomes, leading to endosomal 
swelling and in consequence endosomal rupture. A positive concomitant effect of the 
formulation of the siRNA construct with 386 is the increased size of the complexes 
(Figure 34). After systemic application, plain FA-PEG-siRNA with a hydrodynamic 
size < 10 nm would rapidly be cleared from blood circulation by the kidneys, 
hindering receptor mediated uptake into the desired tissue, e.g. distant tumor tissue. 
The concept of linking targeting ligands directly to siRNA for receptor specific cellular 
uptake has previously been described [153-155], but the systems lacked structural 
precision due to the chosen synthesis route or insufficient purification. The present 
work combines a high degree of purity and structural definition for both components, 
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siRNA conjugate and oligomer, yielding reliable and reproducible data for clear 
structure-activity relationships of the delivery system. The high efficiency of this 
targeted siRNA system, even at low siRNA dosages, shows its potential for future in 
vivo applications. 
 
4.3.2 Influenza peptide – siRNA conjugate 
Incorporation of membrane active moieties like fatty acids [95, 147] or lytic peptides 
[119, 156, 157] into siRNA carriers has proven to facilitate endosomal release and 
enhance gene silencing efficiency of the internalized particles. Instead of attaching 
this functionality to the carrier, with possible complications during synthesis due to 
multiple modification steps of the carrier, our group attached the lytic peptide INF7 
[139] directly to activated siRNA in a straightforward procedure by disulfide linkage 
and subsequent purification by HPLC (see Diss. Dohmen 2012). The resulting 
membrane active INF-siRNA conjugate enables the use of carriers like oligomer 76, 
which cannot promote sufficient endosomal release, for efficient gene silencing. Lytic 
activity of INF7 and functionality of the coupled siRNA were not affected by the 
hybridization (see Diss. Dohmen 2012), enabling the use of the construct in 
polyplexes with full efficiency of both components. The membrane disruptive 
character of INF-siRNA at endosomal pH of 5 releases polyplexes into the cytosol, 
which would otherwise face endo-/lysosomal degradation (Figure 38 and 39). After 
cleavage of the reducible disulfide bond between the modified influenza peptide and 
siRNA, caused by elevated glutathione levels in the cytosol, the antisense strand of 
the nucleic acid can be incorporated into the silencing complex and take action 
without impairment from the modification. Necessity of the reducible disulfide bond 
was demonstrated by the reduced gene silencing activity of an INF-siRNA analog 
with stable maleimido linkage (Figure 41). 
Transfection efficiency of a polycationic carrier can vary in different cell lines, 
amongst others because of variations in endosomal acidification, impacting the 
protonation degree of the polycationic carrier and endosomal swelling, causing 
differences in endosomal escape. When the buffering capacity and membrane 
interaction of the carrier in a specific cell line is not sufficient for effective endosomal 
rupture, the combination with INF-siRNA can boost transfection efficiency, like shown 
with three-armed oligomer 386 in KB cells (Figure 40). Without lytic component, 386 
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polyplexes are completely dependent on the proton sponge effect and interaction of 
the oligomer with the endosomal membrane, as it contains no additional functional 
groups like lipid modification for enhanced membrane destabilization. For this type of 
carrier, the functionalization of siRNA with INF7 is a useful endorsement, yielding 
efficient siRNA delivery systems. 
As endosomal escape is a major bottleneck in polymeric siRNA delivery, the INF-
siRNA conjugate presents an effective agent for overcoming this critical hurdle in the 
delivery process. With regard to shielded polyplexes, e.g. by PEGylation, this 
becomes even more important, as shielding reduces the interaction between 
polycationic carriers and the cell membrane, which is favorable in the extracellular 
environment for a prolonged circulation half life in the blood stream but 
disadvantageous after cellular internalization. Within endosomes, strong interaction 
between cationic carrier and endosomal membrane is required for destabilization of 
the membrane. This “PEG dilemma” can be solved by the use of additional 
membrane active agents like the INF-siRNA conjugate. 
 
 
4.3.3 Folate receptor targeted, defined carrier for receptor mediated 
uptake of lytic INF-siRNA 
For efficient systemic delivery of siRNA to a specific tissue a polycationic carrier 
system has to be functionalized and bioresponsive in order to adapt to the changing 
environment and requirements in the course of the delivery process. Several 
examples of bioresponsive systems have been reported for siRNA delivery [31, 95, 
146, 158] but the various introduced functional domains increased the polydispersity 
of these constructs even beyond the original poor definition of the cationic carrier. 
The discussed sequence defined, folic acid receptor targeted, PEGylated, 
polycationic carrier 356, in combination with lytic INF-siRNA, proved to be a 
promising approach, maintaining the sequence defined character of the carrier 
platform even after functionalization. This system addresses several critical 
bottlenecks in siRNA delivery. Strong siRNA binding and stable polyplex formation is 
provided by the oligomer backbone with 8 Stp building blocks and a terminal 
cysteines at the end for crosslinking during polyplex formation. PEGylation of the 
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cationic backbone masks the positive surface charge of the polyplexes, reducing 
unspecific interactions of the polyplexes with blood components and prolonging 
circulation half life (see Diss. Dohmen 2012). The targeting moiety folic acid at the 
distal end of the PEG chain ensured receptor specific attachment and uptake into 
folic acid receptor positive cells (Figure 43 and 44). The construct is assembled by 
solid phase peptide synthesis, using defined building blocks. This ensures the 
reliability and reproducibility of the results and at the same time allows the assembly 
of mutated sequences of the construct, depleting one functional group at a time. This 
way, exact structure-activity relationship studies can be performed. Two different 
analogs of 356 were synthesized in parallel to the original construct, one without 
targeting ligand, the other one lacking cysteines for crosslinking. Complexes of the 
analogs with siRNA were not internalized and did not mediate gene silencing, 
highlighting the necessity of these functional groups for the intracellular delivery of 
siRNA (Figure 43, 44 and 45). Oligomer 356 however also showed very moderate 
gene silencing ability with regular siRNA. Obviously, the structure of the oligomer 
plus PEGylation of the construct does not support endosomal escape of the 
polyplexes [140, 141]. Only the combination with INF-siRNA facilitated efficient 
endosomal escape, once the polyplexes had been internalized in endosomes, 
leading to strong reporter gene knockdown (Figure 45). Unspecific gene silencing 
was ruled out by receptor competition experiments and the absence of gene 
silencing ability in Neuro2A-eGFPLuc cells with low folic acid receptors status. 
Encouraged by the high gene silencing efficiency and good biocompatibility of the 
construct in cell culture, systemic in vivo delivery experiments were conducted in KB 
tumor bearing mice, which revealed that the polyplexes were rapidly cleared from the 
blood circulation before reaching tumor tissue, due to their small size. Short 
circulation time dramatically reduces the therapeutic potential of such targeted 
systems. Therefore the size of the particles was increased by elongation of the PEG 
chain with one or two additional PEG24 molecules (see Diss. Dohmen 2012). PEG24 
was chosen because it is the longest available defined PEG chain, maintaining the 
monomolecular shape of the construct. Gene silencing experiments demonstrated 
that the higher degree of PEGylation did not affect knockdown efficiency of the 
polyplexes (Figure 47), opening up the possibility for further systemic delivery 
experiments. 
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5 SUMMARY 
 
Nucleic acids like siRNA embody a next step in biological treatment options, following 
proteins and peptides. For resounding success of these new entities, appropriate 
delivery agents are essential for accumulation of the payload inside target cells. 
Polymers represent an interesting class of carriers for achieving this goal. In this 
thesis, improved as well as novel delivery systems, based on polycationic carriers, 
were discovered and evaluated for efficient delivery of siRNA. 
The reported pseudodendritic, biodegradable polymer HD-O, consisting of 
oligoethylenimine building blocks, had previously demonstrated effective gene 
delivery of pDNA but lacked gene silencing efficiency when complexed with siRNA in 
the present study. Reason for this was insufficient stability of the resulting polyplexes. 
In situ lateral stabilization of the resulting polyplexes by the amine reactive 
crosslinker DSP improved stability of the complexes, which led to greatly improved 
delivery efficiency and reporter gene knockdown. Biodegradability of the polymer 
after linker stabilization is maintained by disulfide bonds in the crosslinking agent. 
This study underlines the importance of stability of siRNA nanoparticles for delivery 
efficiency as one of the major bottlenecks in the delivery process. One of the 
drawbacks of this and other reported polycationic carriers is the polydispersity of the 
polymers, making batch comparisons and reproducibility difficult. Therefore the 
developed concept of crosslinking for increased stability of siRNA polyplexes was 
transferred to a novel class of sequence defined oligomers, incorporating additional 
functional groups for enhanced siRNA delivery. 
By exploiting solid-phase supported peptide synthesis, sequence defined, 
monodisperse oligo (ethane amino) amides were assembled, using different novel 
non-peptidic building blocks, and various molecular shapes were tested for structure-
activity relationships in siRNA delivery. Efficient reporter gene knockdown was 
obtained in a variety of cell lines using either branched three-armed structures, or 
lipid-modified structures with i-shape, T-shape, U-shape configuration. For the 
majority of structures, apart from U-shapes, the presence of cysteines was strictly 
required for lateral polyplex stabilization and silencing activity, like previously also 
found for the HD-O polyplexes. Although all four tested building blocks contain the 
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ethylenediamine proton sponge motif, only oligomers assembled with the 
tetraethylenepentamine based amino acids (Stp, Gtp, Ptp) but not with the 
triethylenetetramine based amino acid (Gtt) were able to mediate efficient gene 
silencing. For the lipopolymeric structures, out of the tested saturated (from C4 to 
C18) and unsaturated (C18) fatty acid moieties, two proximate oleic acids or linolic 
acids provided the oligomers with the best gene silencing activity and also pH 
specific lytic activity at pH 5.5, presumably facilitating endosomal escape of the 
polyplexes. Evaluation of oligomer chain length revealed a minimal number of at 
least two oligo (ethane amino) building blocks per oligomer arm as necessary for the 
vast majority of structures, but only marginal changes were found with higher 
numbers. Molecular topology of the oligomers played a subordinate role in delivery 
efficiency compared to the effect of incorporating different building blocks and 
functional groups. The high efficiency of these defined delivery systems even at low 
siRNA dosages, in combination with low cytotoxicity, makes them promising 
candidates for in vivo applications. Proven serum stability of the polyplexes 
strengthens their potential as systemic siRNA delivery agents. 
Changing requirements during the delivery process of siRNA request the 
functionalization of polyplexes, allowing adaptation to the different biological 
surroundings. The first important step, selective uptake into target cells, can be 
achieved by incorporation of targeting ligands, e.g. folic acid, targeting the folic acid 
receptor. The FA-PEG-siRNA conjugate, in combination with a three-armed oligomer 
from the novel oligomer series, showed selective uptake and efficient gene silencing 
in folic acid receptor positive cells. The PEG spacer of the conjugate reduced the 
overall positive surface charge of polyplexes, thereby minimizing unspecific 
interactions with blood components or cell surfaces. 
Another major barrier in siRNA delivery is effective escape from the endosomal 
compartment. Coupling the membrane active peptide INF7 directly to siRNA via 
degradable disulfide linkage boosted endosomal escape ability of otherwise 
ineffective oligomeric systems, facilitating siRNA mediated reporter gene silencing in 
vitro. 
Ideally, a siRNA carrier system should comprise functionalities for all essential steps 
during the delivery process: efficient binding of siRNA into stable polyplexes, 
shielding of the polyplex during circulation, a targeting moiety for receptor specific 
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cellular uptake and finally effective release of the payload from the endosomal 
compartment. An approach to realize this kind of multifunctional system is the folic 
acid receptor targeted, PEG shielded carrier 356, assembled by solid phase 
supported synthesis, in combination with INF-siRNA. The Stp-based polycationic 
oligomer with two cysteines for crosslinking during polyplex formation mediated 
receptor specific cellular uptake of INF-siRNA, resulting in strong gene silencing. 
High purity of the entities and sequence defined structures allowed to study the 
impact of every single functional domain on delivery efficiency. Based on the applied 
synthesis strategy and the findings of this study, further rational design of novel 
potent carriers can be achieved by introducing new cationic building blocks, 
elongation of the polymeric backbone or screening of new functional domains.
Appendix                                                                                            
 
 
92 
6 APPENDIX 
6.1 Abbreviations 
A   alanine 
ACTB   beta-actine (gene name) 
AHA1   activator of 90 kDa heat shock protein ATPase isoform 1 
Boc   tert-butyloxycarbonyl 
brPEI   branched polyethylenimine (25 kDa) 
ButA   butyric acid 
C   cysteine 
CapA   caprylic acid 
DAPI   4,6-Diamidin-2-phenylindol 
DLS    dynamic light scattering 
DMEM   Dulbecco’s Modified Eagle’s Medium 
DMSO   dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
DOPE   dioleoyl-phosphatidylethanolamine 
DOTAP  dioleoyl-trimethylammoniumpropane 
DSP    dithiobis (succinimidylpropionate) 
DSPC   distearoyl-glycero-3-phosphocholine 
dsRNA  double stranded ribonucleic acid 
DSS    disuccinimidyl suberate 
EDTA   ethylenediaminetetraacetate 
eGFP   enhanced green fluorescent protein 
EtBr    ethidium bromide 
FA   folic acid 
FACS   fluorescence-activated cell sorting 
FBS   fetal bovine serum 
FCS    fetal calf serum 
Fmoc   fluorenylmethyloxycarbonyl chloride 
FOLR-1  human folic acid receptor 1 
HBG    HEPES-buffered glucose 
HD    hexanediol-diacrylate 
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HEPES   N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic acid) 
HPLC   high pressure liquid chromatography 
K   lysine 
LinA   linolic acid 
linPEI    linear PEI (22 kDa) 
Luc    luciferase 
miRNA   micro RNA 
mRNA   messenger RNA 
MTT    dimethylthiazolyldiphenyl-tetrazolium bromide 
MW    molecular weight 
MyrA   myristic acid 
NEM   N-ethyl maleimide 
N/P-ratio   molar ratio of nitrogen to phosphate (conjugate to nucleic acid) 
OEI    oligoethylenimine 
OEI 800   OEI (800 Da) 
OleA   oleic acid 
PAMAM  polyamidoamines 
PBS    phosphate-buffered saline 
pDNA   plasmid DNA 
PEI    polyethylenimine 
PEG    polyethylene glycol 
PEG24  polyethylene glycol with 24 ethylene glycol units 
PLL    poly-L-lysine 
poly-IC   poly-inosine-cytosine 
RISC    RNA-induced silencing complex 
RLU    relative light units 
RNA    ribonucleic acid 
RNAi   RNA interference 
RPMI   Roswell Park Memorial Institute 
RT-qPCR   reverse transcriptase quantitative polymerase chain reaction 
siRNA   small interfering RNA 
SPDP   succinimidyl 3-(2-pyridyldithio) propionate 
sPEI   succinilated branched PEI (25 kDa) 
Appendix                                                                                            
 
 
94 
SPPS   solid phase peptide synthesis 
SteA   stearic acid 
Tf    transferrin 
TNBS   trinitrobenzenesulfonic acid 
w/w ratio   weight to weight ratio (conjugate to nucleic acid) 
Appendix                                                                                            
 
 
95 
6.2 Publications 
6.2.1 Original papers 
Russ V, Fröhlich T, Li Y, Halama A, Ogris M, Wagner E (2010) Improved in vivo gene 
transfer into tumor tissue by stabilization of pseudodendritic oligoethylenimine-based 
polyplexes. J Gene Med 2010 Feb; 12 (2); 180-93. 
 
Schaffert D, Troiber C, Salcher EE, Fröhlich T, Martin I, Badgujar N, Dohmen C, 
Edinger D, Kläger R, Maiwald G, Farkasova K, Seeber S, Jahn-Hofmann K, 
Hadwiger P, Wagner E (2011) Solid-Phase Synthesis of Sequence-Defined T-, i-, 
and U-Shape Polymers for pDNA and siRNA Delivery. Angew Chem Int Ed Engl. 
2011 Sep 12; 50 (38): 8986-9. 
 
Dohmen C, Fröhlich T, Lächelt U, Röhl I, Vornlocher HP, Hadwiger P, Wagner E 
(2012) Defined Folate-PEG-siRNA Conjugates for Receptor Specific Gene Silencing. 
Mol. Ther. – Nucleic Acids. 1e7 
 
Fröhlich T, Edinger D, Kläger R, Troiber C, Salcher E, Badgujar N, Martin I, Schaffert 
D, Cengizeroglu A, Hadwiger P, Vornlocher HP, Wagner E (2012) Structure-activity 
relationships of siRNA carriers based on sequence-defined oligo (ethane amino) 
amides. J Control Rel. In press 
 
Dohmen C, Edinger D, Fröhlich T, Schreiner L, Lächelt U, Troiber C, Rädler J, 
Hadwiger P, Vornlocher HP, Wagner E Nano sized multifunctional polyplexes for 
receptor mediated siRNA delivery. In revision 
 
Fröhlich T, Edinger D, Russ V, Wagner E Stabilization of polyplexes via lateral 
crosslinking for efficient siRNA delivery. Submitted 
 
Salcher E, Kos P, Fröhlich T, Badgujar N, Scheible M, Wagner E Sequence-defined 
Four-arm Oligo(ethanamino)amides for pDNA and siRNA Delivery: Impact of Building 
Blocks on Efficacy. In revision 
Appendix                                                                                            
 
 
96 
6.2.2 Reviews 
Fröhlich T, Wagner E (2010) Peptide- and polymer-based delivery of therapeutic 
RNA. Soft Matter, 2010, 6 (2), 226-234. 
 
 
6.2.3 Abstracts 
Maier K, Fröhlich T, Russ V, Li Y, Halama A, Ogris M, Schaffert D, Schlossbauer A, 
Bein T, Wagner E: Biocompatible Nanosystems for Nucleic Acid & Protein Delivery. 
Third Annual Symposium on Nanobiotechnology: New Directions in NanoHealth, 
2009, California NanoSystems Institute, UCLA, Los Angeles, USA (poster 
presentation). 
 
Dohmen C, Fröhlich T, Foralosso R, Wagner E: pH-Labile Degradable 
Pseudodendritic Polycations for In Vitro and In Vivo DNA Delivery into Cancer Cells. 
17th Annual Meeting German Society for Gene Therapy (DG-GT e.V.), October 7–9, 
2010, LMU, Munich, Germany (poster presentation). 
 
Fröhlich T, Phillip A, Russ V, Edinger D, Wagner E: Biodegradable Pseudodendritic 
Oligoamines for siRNA Delivery. 17th Annual Meeting German Society for Gene 
Therapy (DG-GT e.V.), October 7–9, 2010, LMU, Munich, Germany (poster 
presentation). 
References                                                                                            
 
 
97 
7 REFERENCES 
 
[1] R.M. Blaese, K.W. Culver, A.D. Miller, C.S. Carter, T. Fleisher, M. Clerici, G. 
Shearer, L. Chang, Y. Chiang, P. Tolstoshev, T lymphocyte-directed gene therapy for 
ADA- SCID: initial trial results after 4 years. Science 270(5235) (1995) 475-480. 
[2] J. Rosenecker, S. Huth, C. Rudolph, Gene therapy for cystic fibrosis lung 
disease: current status and future perspectives. Curr.Opin.Mol Ther 8(5) (2006) 439-
445. 
[3] D.W. Scott, J.N. Lozier, Gene therapy for haemophilia: prospects and 
challenges to prevent or reverse inhibitor formation. Br J Haematol 156(3) 295-302. 
[4] D.S. Strayer, R. Akkina, B.A. Bunnell, B. Dropulic, V. Planelles, R.J. 
Pomerantz, J.J. Rossi, J.A. Zaia, Current status of gene therapy strategies to treat 
HIV/AIDS. Mol Ther 11(6) (2005) 823-842. 
[5] L.J. Scherer, J.J. Rossi, Ex vivo gene therapy for HIV-1 treatment. Hum Mol 
Genet (2011) 20(R1) R100-107. 
[6] B. Ferraro, M.P. Morrow, N.A. Hutnick, T.H. Shin, C.E. Lucke, D.B. Weiner, 
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 53(3) 
296-302. 
[7] J.A. Sawicki, D.G. Anderson, R. Langer, Nanoparticle delivery of suicide DNA 
for epithelial ovarian cancer therapy. Adv Exp Med Biol 622 (2008) 209-219. 
[8] A. Aigner, Gene silencing through RNA interference (RNAi) in vivo: strategies 
based on the direct application of siRNAs. J Biotechnol 124(1) (2006) 12-25. 
[9] A.R. de Fougerolles, Delivery vehicles for small interfering RNA in vivo. Hum 
Gene Ther 19(2) (2008) 125-132. 
[10] J.C. Burnett, J.J. Rossi, K. Tiemann, Current progress of siRNA/shRNA 
therapeutics in clinical trials. Biotechnol J 6(9) (2011) 1130-1146. 
[11] R. Duncan, R. Gaspar, Nanomedicine(s) under the microscope. Mol Pharm 
(2011) 8(6) 2101-2141. 
[12] A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, C.C. Mello, Potent 
and specific genetic interference by double-stranded RNA in Caenorhabditis elegans 
2. Nature 391(6669) (1998) 806-811. 
[13] P.D. Zamore, T. Tuschl, P.A. Sharp, D.P. Bartel, RNAi: double-stranded RNA 
directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 
101(1) (2000) 25-33. 
[14] S.M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, T. Tuschl, 
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian 
cells 1. Nature 411(6836) (2001) 494-498. 
[15] T. Rand, K. Ginalski, N. Grishin, X. Wang, Biochemical identification of 
Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. 
Proc Natl Acad Sci U S A. 101(40) (2004) 14385-14389. 
[16] S. Hammond, S. Boettcher, A. Caudy, R. Kobayashi, G. Hannon, Argonaute2, 
a link between genetic and biochemical analyses of RNAi. Science 293(5532) (2001) 
1146-1150. 
[17] Y. Wang, G. Sheng, S. Juranek, T. Tuschl, D.J. Patel, Structure of the guide-
strand-containing argonaute silencing complex. Nature 456(7219) (2008) 209-213. 
[18] L. Li, Y. Shen, Overcoming obstacles to develop effective and safe siRNA 
therapeutics. Expert Opin Biol Ther. 9(5) (2009) 609-619. 
References                                                                                            
 
 
98 
[19] H. Ulrich, C.A. Trujillo, A.A. Nery, J.M. Alves, P. Majumder, R.R. Resende, 
A.H. Martins, DNA and RNA aptamers: from tools for basic research towards 
therapeutic applications. Comb.Chem High Throughput.Screen. 9(8) (2006) 619-632. 
[20] B. Weiss, G. Davidkova, L. Zhou, Antisense RNA gene therapy for studying 
and modulating biological processes. Cell Mol Life Sci 55(3) (1999) 334-358. 
[21] H. Yin, Q. Lu, M. Wood, Effective exon skipping and restoration of dystrophin 
expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 
16(1) (2008) 38-45. 
[22] J. Krützfeldt, N. Rajewsky, R. Braich, K. Rajeev, T. Tuschl, M. Manoharan, M. 
Stoffel, Silencing of microRNAs in vivo with 'antagomirs'. Nature 438(7068) (2005) 
685-689. 
[23] A. Shir, M. Ogris, E. Wagner, A. Levitzki, EGF receptor-targeted synthetic 
double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma 
tumors in mice. PLoS Med 3(1) (2006) e6. 
[24] D. Schaffert, M. Kiss, W. Rodl, A. Shir, A. Levitzki, M. Ogris, E. Wagner, 
Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing 
tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier. Pharm Res 
28(4) (2011) 731-741. 
[25] H. Poeck, R. Besch, C. Maihoefer, M. Renn, D. Tormo, S. Morskaya, S. 
Kirschnek, E. Gaffal, J. Landsberg, J. Hellmuth, A. Schmidt, D. Anz, M. Bscheider, T. 
Schwerd, C. Berking, C. Bourquin, U. Kalinke, E. Kremmer, H. Kato, S. Akira, R. 
Meyers, G. Häcker, M. Neuenhahn, D. Busch, J. Ruland, S. Rothenfusser, M. Prinz, 
V. Hornung, S. Endres, T. Tüting, G. Hartmann, 5'-Triphosphate-siRNA: turning gene 
silencing and Rig-I activation against melanoma. Nat Med 14(11) (2008) 1256-1263. 
[26] R. Besch, H. Poeck, T. Hohenauer, D. Senft, G. Häcker, C. Berking, V. 
Hornung, S. Endres, T. Ruzicka, S. Rothenfusser, G. Hartmann, Proapoptotic 
signaling induced by RIG-I and MDA-5 results in type I interferon-independent 
apoptosis in human melanoma cells. J Clin Invest 119 (8) (2009) 2399-411. 
[27] M. Tolentino, A. Brucker, J. Fosnot, G. Ying, I. Wu, G. Malik, S. Wan, S. 
Reich, Intravitreal injection of vascular endothelial growth factor small interfering RNA 
inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal 
neovascularization. Retina 24(1) (2004) 132-138. 
[28] K. Nishina, T. Unno, Y. Uno, T. Kubodera, T. Kanouchi, H. Mizusawa, T. 
Yokota, Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-
tocopherol. Mol Ther. 16(4) (2008) 734-740. 
[29] J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, 
S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, M. John, V. Kesavan, G. Lavine, 
R.K. Pandey, T. Racie, K.G. Rajeev, I. Rohl, I. Toudjarska, G. Wang, S. Wuschko, D. 
Bumcrot, V. Koteliansky, S. Limmer, M. Manoharan, H.P. Vornlocher, Therapeutic 
silencing of an endogenous gene by systemic administration of modified siRNAs. 
Nature 432(7014) (2004) 173-178. 
[30] M.E. Davis, J.E. Zuckerman, C.H. Choi, D. Seligson, A. Tolcher, C.A. Alabi, Y. 
Yen, J.D. Heidel, A. Ribas, Evidence of RNAi in humans from systemically 
administered siRNA via targeted nanoparticles. Nature 464(7291) (2010) 1067-1070. 
[31] D.B. Rozema, D.L. Lewis, D.H. Wakefield, S.C. Wong, J.J. Klein, P.L. Roesch, 
S.L. Bertin, T.W. Reppen, Q. Chu, A.V. Blokhin, J.E. Hagstrom, J.A. Wolff, Dynamic 
PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. 
Proc.Natl.Acad.Sci U.S.A 104(32) (2007) 12982-12987. 
[32] E. Wagner, Polymers for siRNA delivery: Inspired by viruses to be targeted, 
dynamic and precise. Acc. Chem. Res. in press (2012) DOI 10.1021/ar2002232. 
References                                                                                            
 
 
99 
[33] R. Schiffelers, A. Ansari, J. Xu, Q. Zhou, Q. Tang, G. Storm, G. Molema, P. 
Lu, P. Scaria, M. Woodle, Cancer siRNA therapy by tumor selective delivery with 
ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32(19) (2004) 
e149. 
[34] O.M. Merkel, D. Librizzi, A. Pfestroff, T. Schurrat, K. Buyens, N.N. Sanders, 
S.C. De Smedt, M. Behe, T. Kissel, Stability of siRNA polyplexes from 
poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo 
conditions: effects on pharmacokinetics and biodistribution measured by 
Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed 
Tomography (SPECT) imaging. J Control Release 138(2) (2009) 148-159. 
[35] A.K. Varkouhi, G. Mountrichas, R.M. Schiffelers, T. Lammers, G. Storm, S. 
Pispas, W.E. Hennink, Polyplexes based on cationic polymers with strong nucleic 
acid binding properties. Eur J Pharm Sci 45 (4) (2012) 459-66. 
[36] G. Creusat, A.S. Rinaldi, E. Weiss, R. Elbaghdadi, J.S. Remy, R. Mulherkar, 
G. Zuber, Proton sponge trick for pH-sensitive disassembly of polyethylenimine-
based siRNA delivery systems. Bioconjug Chem 21(5) (2010) 994-1002. 
[37] T.S. Zimmermann, A.C. Lee, A. Akinc, B. Bramlage, D. Bumcrot, M.N. 
Fedoruk, J. Harborth, J.A. Heyes, L.B. Jeffs, M. John, A.D. Judge, K. Lam, K. 
McClintock, L.V. Nechev, L.R. Palmer, T. Racie, I. Rohl, S. Seiffert, S. Shanmugam, 
V. Sood, J. Soutschek, I. Toudjarska, A.J. Wheat, E. Yaworski, W. Zedalis, V. 
Koteliansky, M. Manoharan, H.P. Vornlocher, I. MacLachlan, RNAi-mediated gene 
silencing in non-human primates. Nature 441(7089) (2006) 111-114. 
[38] Y. Sato, K. Murase, J. Kato, M. Kobune, T. Sato, Y. Kawano, R. Takimoto, K. 
Takada, K. Miyanishi, T. Matsunaga, T. Takayama, Y. Niitsu, Resolution of liver 
cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-
specific chaperone. Nat Biotechnol 26(4) (2008) 431-442. 
[39] H.J. Kim, A. Ishii, K. Miyata, Y. Lee, S. Wu, M. Oba, N. Nishiyama, K. 
Kataoka, Introduction of stearoyl moieties into a biocompatible cationic 
polyaspartamide derivative, PAsp(DET), with endosomal escaping function for 
enhanced siRNA-mediated gene knockdown. J Control Release 145(2) (2010) 141-
148. 
[40] X.L. Wang, S. Ramusovic, T. Nguyen, Z.R. Lu, Novel polymerizable 
surfactants with pH-sensitive amphiphilicity and cell membrane disruption for efficient 
siRNA delivery. Bioconjug Chem 18(6) (2007) 2169-2177. 
[41] A. Philipp, X. Zhao, P. Tarcha, E. Wagner, A. Zintchenko, Hydrophobically 
modified oligoethylenimines as highly efficient transfection agents for siRNA delivery. 
Bioconjug Chem 20(11) (2009) 2055-2061. 
[42] K.T. Love, K.P. Mahon, C.G. Levins, K.A. Whitehead, W. Querbes, J.R. 
Dorkin, J. Qin, W. Cantley, L.L. Qin, T. Racie, M. Frank-Kamenetsky, K.N. Yip, R. 
Alvarez, D.W. Sah, A. de Fougerolles, K. Fitzgerald, V. Koteliansky, A. Akinc, R. 
Langer, D.G. Anderson, Lipid-like materials for low-dose, in vivo gene silencing. Proc 
Natl Acad Sci U S A 107(5) (2010) 1864-1869. 
[43] D. Bumcrot, M. Manoharan, V. Koteliansky, D.W. Sah, RNAi therapeutics: a 
potential new class of pharmaceutical drugs. Nat.Chem Biol 2(12) (2006) 711-719. 
[44] M. Robbins, A. Judge, I. MacLachlan, siRNA and innate immunity. 
Oligonucleotides 19(2) (2009) 89-102. 
[45] A.D. Judge, V. Sood, J.R. Shaw, D. Fang, K. McClintock, I. MacLachlan, 
Sequence-dependent stimulation of the mammalian innate immune response by 
synthetic siRNA. Nat Biotechnol 23(4) (2005) 457-462. 
References                                                                                            
 
 
100 
[46] J. Burchard, A. Jackson, V. Malkov, R. Needham, Y. Tan, S. Bartz, H. Dai, A. 
Sachs, P. Linsley, MicroRNA-like off-target transcript regulation by siRNAs is species 
specific. RNA 15(2) (2009) 308-315. 
[47] A.D. Judge, G. Bola, A.C. Lee, I. MacLachlan, Design of noninflammatory 
synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13(3) (2006) 494-
505. 
[48] M. Manoharan, A. Akinc, R.K. Pandey, J. Qin, P. Hadwiger, M. John, K. Mills, 
K. Charisse, M.A. Maier, L. Nechev, E.M. Greene, P.S. Pallan, E. Rozners, K.G. 
Rajeev, M. Egli, Unique gene-silencing and structural properties of 2'-fluoro-modified 
siRNAs. Angew Chem Int Ed Engl 50(10) (2011) 2284-2288. 
[49] D. Braasch, S. Jensen, Y. Liu, K. Kaur, K. Arar, M. White, D. Corey, RNA 
interference in mammalian cells by chemically-modified RNA. Biochemistry 42(26) 
(2003) 7967-7975. 
[50] A. Jackson, J. Burchard, D. Leake, A. Reynolds, J. Schelter, J. Guo, J. 
Johnson, L. Lim, J. Karpilow, K. Nichols, W. Marshall, A. Khvorova, P. Linsley, 
Position-specific chemical modification of siRNAs reduces "off-target" transcript 
silencing. RNA 12(7) (2006) 1197-1205. 
[51] M. Robbins, A. Judge, L. Liang, K. McClintock, E. Yaworski, I. MacLachlan, 2'-
O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther. 15(9) (2007) 1663-
1669. 
[52] J. Bramsen, M. Laursen, A. Nielsen, T. Hansen, C. Bus, N. Langkjaer, B. 
Babu, T. Højland, M. Abramov, A. Van Aerschot, D. Odadzic, R. Smicius, J. Haas, C. 
Andree, J. Barman, M. Wenska, P. Srivastava, C. Zhou, D. Honcharenko, S. Hess, 
E. Müller, G. Bobkov, S. Mikhailov, E. Fava, T. Meyer, J. Chattopadhyaya, M. Zerial, 
J. Engels, P. Herdewijn, J. Wengel, J. Kjems, A large-scale chemical modification 
screen identifies design rules to generate siRNAs with high activity, high stability and 
low toxicity. Nucleic Acids Res 37(9) (2009) 2867-2881. 
[53] D. Kim, M. Behlke, S. Rose, M. Chang, S. Choi, J. Rossi, Synthetic dsRNA 
Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 23(2) (2005) 
222-226. 
[54] X. Sun, H. Rogoff, C. Li, Asymmetric RNA duplexes mediate RNA interference 
in mammalian cells. Nat Biotechnol 26(12) (2008) 1379-1382. 
[55] J. Bramsen, M. Laursen, C. Damgaard, S. Lena, B. Babu, J. Wengel, J. 
Kjems, Improved silencing properties using small internally segmented interfering 
RNAs. Nucleic Acids Res 35(17) (2007) 5886-5897. 
[56] D. Edinger, E. Wagner, Bioresponsive polymers for the delivery of therapeutic 
nucleic acids. Wiley Interdiscip Rev Nanomed Nanobiotechnol 3(1) (2011) 33-46. 
[57] C. Troiber, E. Wagner, Nucleic acid carriers based on precise polymer 
conjugates. Bioconjug Chem 22(9) (2011) 1737-1752. 
[58] M.R. Lares, J.J. Rossi, D.L. Ouellet, RNAi and small interfering RNAs in 
human disease therapeutic applications. Trends Biotechnol 28(11) (2010) 570-579. 
[59] X. Yuan, S. Naguib, Z. Wu, Recent advances of siRNA delivery by 
nanoparticles. Expert Opin Drug Deliv 8(4) (2011) 521-536. 
[60] I.M. Hafez, N. Maurer, P.R. Cullis, On the mechanism whereby cationic lipids 
promote intracellular delivery of polynucleic acids. Gene Ther 8(15) (2001) 1188-
1196. 
[61] S. Sonoke, T. Ueda, K. Fujiwara, Y. Sato, K. Takagaki, K. Hirabayashi, T. 
Ohgi, J. Yano, Tumor regression in mice by delivery of Bcl-2 small interfering RNA 
with pegylated cationic liposomes. Cancer Res 68(21) (2008) 8843-8851. 
References                                                                                            
 
 
101 
[62] J. Heyes, L. Palmer, K. Bremner, I. MacLachlan, Cationic lipid saturation 
influences intracellular delivery of encapsulated nucleic acids. J Control Release 
107(2) (2005) 276-287. 
[63] M.C. Pedroso de Lima, S. Simoes, P. Pires, H. Faneca, N. Duzgunes, Cationic 
lipid-DNA complexes in gene delivery: from biophysics to biological applications. 
Adv.Drug Deliv.Rev. 47(2-3) (2001) 277-294. 
[64] A. Santel, M. Aleku, O. Keil, J. Endruschat, V. Esche, B. Durieux, K. Loffler, M. 
Fechtner, T. Rohl, G. Fisch, S. Dames, W. Arnold, K. Giese, A. Klippel, J. Kaufmann, 
RNA interference in the mouse vascular endothelium by systemic administration of 
siRNA-lipoplexes for cancer therapy. Gene Ther 13(18) (2006) 1360-1370. 
[65] M. Aleku, P. Schulz, O. Keil, A. Santel, U. Schaeper, B. Dieckhoff, O. Janke, J. 
Endruschat, B. Durieux, N. Roder, K. Loffler, C. Lange, M. Fechtner, K. Mopert, G. 
Fisch, S. Dames, W. Arnold, K. Jochims, K. Giese, B. Wiedenmann, A. Scholz, J. 
Kaufmann, Atu027, a liposomal small interfering RNA formulation targeting protein 
kinase N3, inhibits cancer progression. Cancer Res 68(23) (2008) 9788-9798. 
[66] E. Wagner, M. Cotten, R. Foisner, M.L. Birnstiel, Transferrin-polycation-DNA 
complexes: the effect of polycations on the structure of the complex and DNA 
delivery to cells. Proc.Natl.Acad.Sci.U.S.A 88(10) (1991) 4255-4259. 
[67] O. Boussif, F. Lezoualc'h, M.A. Zanta, M.D. Mergny, D. Scherman, B. 
Demeneix, J.P. Behr, A versatile vector for gene and oligonucleotide transfer into 
cells in culture and in vivo: polyethylenimine. Proc.Natl.Acad.Sci.U.S.A 92(16) (1995) 
7297-7301. 
[68] A.C. Grayson, A.M. Doody, D. Putnam, Biophysical and structural 
characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm.Res. 
23(8) (2006) 1868-1876. 
[69] B. Urban-Klein, S. Werth, S. Abuharbeid, F. Czubayko, A. Aigner, RNAi-
mediated gene-targeting through systemic application of polyethylenimine (PEI)-
complexed siRNA in vivo. Gene Ther. 12(5) (2005) 461-466. 
[70] M. Grzelinski, B. Urban-Klein, T. Martens, K. Lamszus, U. Bakowsky, S. 
Hobel, F. Czubayko, A. Aigner, RNA interference-mediated gene silencing of 
pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo 
exerts antitumoral effects in glioblastoma xenografts. Hum.Gene Ther. 17(7) (2006) 
751-766. 
[71] M. Thomas, J.J. Lu, Q. Ge, C. Zhang, J. Chen, A.M. Klibanov, Full deacylation 
of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to 
mouse lung. Proc.Natl.Acad.Sci.U.S.A 102(16) (2005) 5679-5684. 
[72] A.L. Bolcato-Bellemin, M.E. Bonnet, G. Creusat, P. Erbacher, J.P. Behr, Sticky 
overhangs enhance siRNA-mediated gene silencing. Proc.Natl.Acad.Sci U.S.A 
104(41) (2007) 16050-16055. 
[73] A. Zintchenko, A. Philipp, A. Dehshahri, E. Wagner, Simple Modifications of 
Branched PEI Lead to Highly Efficient siRNA Carriers with Low Toxicity. Bioconjug 
Chem 19(7) (2008) 1448-1455. 
[74] A. Akinc, A. Zumbuehl, M. Goldberg, E.S. Leshchiner, V. Busini, N. Hossain, 
S.A. Bacallado, D.N. Nguyen, J. Fuller, R. Alvarez, A. Borodovsky, T. Borland, R. 
Constien, A. de Fougerolles, J.R. Dorkin, J.K. Narayanannair, M. Jayaraman, M. 
John, V. Koteliansky, M. Manoharan, L. Nechev, J. Qin, T. Racie, D. Raitcheva, K.G. 
Rajeev, D.W. Sah, J. Soutschek, I. Toudjarska, H.P. Vornlocher, T.S. Zimmermann, 
R. Langer, D.G. Anderson, A combinatorial library of lipid-like materials for delivery of 
RNAi therapeutics. Nat.Biotechnol. 26(5) (2008) 561-569. 
References                                                                                            
 
 
102 
[75] J. Zhou, J. Wu, N. Hafdi, J. Behr, P. Erbacher, L. Peng, PAMAM dendrimers 
for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb)(22) 
(2006) 2362-2364. 
[76] X.X. Liu, P. Rocchi, F.Q. Qu, S.Q. Zheng, Z.C. Liang, M. Gleave, J. Iovanna, 
L. Peng, PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce 
potent antiproliferative effects on prostate cancer cells. ChemMedChem 4(8) (2009) 
1302-1310. 
[77] M. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He, T. Minko, Surface-modified 
and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. 
Bioconjug Chem 19(7) (2008) 1396-1403. 
[78] K. Iwaki, K. Shibata, M. Ohta, Y. Endo, H. Uchida, M. Tominaga, R. Okunaga, 
S. Kai, S. Kitano, A small interfering RNA targeting proteinase-activated receptor-2 is 
effective in suppression of tumor growth in a Panc1 xenograft model. Int J Cancer 
122(3) (2008) 658-663. 
[79] E. Kawata, E. Ashihara, S. Kimura, K. Takenaka, K. Sato, R. Tanaka, A. 
Yokota, Y. Kamitsuji, M. Takeuchi, J. Kuroda, F. Tanaka, T. Yoshikawa, T. Maekawa, 
Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth 
of liver metastases of lung cancer. Mol Cancer Ther 7(9) (2008) 2904-2912. 
[80] X. Liu, K. Howard, M. Dong, M. Andersen, U. Rahbek, M. Johnsen, O. 
Hansen, F. Besenbacher, J. Kjems, The influence of polymeric properties on 
chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 28(6) 
(2007) 1280-1288. 
[81] H. Katas, H. Alpar, Development and characterisation of chitosan 
nanoparticles for siRNA delivery. J Control Release 115(2) (2006) 216-225. 
[82] K. Howard, S. Paludan, M. Behlke, F. Besenbacher, B. Deleuran, J. Kjems, 
Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal 
macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther. 
17(1) (2009) 162-168. 
[83] S. Mao, M. Neu, O. Germershaus, O. Merkel, J. Sitterberg, U. Bakowsky, T. 
Kissel, Influence of polyethylene glycol chain length on the physicochemical and 
biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block 
copolymer/SiRNA polyplexes. Bioconjug.Chem. 17(5) (2006) 1209-1218. 
[84] C. Beh, W. Seow, Y. Wang, Y. Zhang, Z. Ong, P. Ee, Y. Yang, Efficient 
delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: 
downregulating mRNA expression level and sensitizing cancer cells to anticancer 
drug. Biomacromolecules 10(1) (2009) 41-48. 
[85] S. Kim, J. Jeong, S. Lee, S. Kim, T. Park, Local and systemic delivery of 
VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. 
J Control Release 129(2) (2008) 107-116. 
[86] O. Taratula, O. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V. Pozharov, 
H. He, T. Minko, Surface-engineered targeted PPI dendrimer for efficient intracellular 
and intratumoral siRNA delivery. J Control Release 140 (3) (2009) 284-93. 
[87] J. DeRouchey, C. Schmidt, G.F. Walker, C. Koch, C. Plank, E. Wagner, J.O. 
Radler, Monomolecular assembly of siRNA and poly(ethylene glycol)-peptide 
copolymers. Biomacromolecules. 9(2) (2008) 724-732. 
[88] M. Noga, D. Edinger, W. Rodl, E. Wagner, G. Winter, A. Besheer, Controlled 
shielding and deshielding of gene delivery polyplexes using hydroxyethyl starch 
(HES) and alpha-amylase. J Control Release (2012). 
References                                                                                            
 
 
103 
[89] J.H. Jeong, M. Lee, W.J. Kim, J.W. Yockman, T.G. Park, Y.H. Kim, S.W. Kim, 
Anti-GAD antibody targeted non-viral gene delivery to islet beta cells. J.Control 
Release 107(3) (2005) 562-570. 
[90] S. Moffatt, C. Papasakelariou, S. Wiehle, R. Cristiano, Successful in vivo 
tumor targeting of prostate-specific membrane antigen with a highly efficient 
J591/PEI/DNA molecular conjugate. Gene Ther. 13(9) (2006) 761-772. 
[91] K.C. Wood, S.M. Azarin, W. Arap, R. Pasqualini, R. Langer, P.T. Hammond, 
Tumor-targeted gene delivery using molecularly engineered hybrid polymers 
functionalized with a tumor-homing peptide. Bioconjug Chem 19(2) (2008) 403-405. 
[92] E. Wagner, M. Zenke, M. Cotten, H. Beug, M.L. Birnstiel, Transferrin-
polycation conjugates as carriers for DNA uptake into cells. Proc.Natl.Acad.Sci.U.S.A 
87(9) (1990) 3410-3414. 
[93] Y. Ikeda, K. Taira, Ligand-targeted delivery of therapeutic siRNA. Pharm.Res. 
23(8) (2006) 1631-1640. 
[94] X. Wang, R. Xu, Z. Lu, A peptide-targeted delivery system with pH-sensitive 
amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. 
J Control Release 134(3) (2008) 207-213. 
[95] X. Wang, R. Xu, X. Wu, D. Gillespie, R. Jensen, Z. Lu, Targeted systemic 
delivery of a therapeutic siRNA with a multifunctional carrier controls tumor 
proliferation in mice. Mol Pharmaceutics 6(3) (2009) 738-746. 
[96] K.F. Pirollo, G. Zon, A. Rait, Q. Zhou, W. Yu, R. Hogrefe, E.H. Chang, Tumor-
targeting nanoimmunoliposome complex for short interfering RNA delivery. 
Hum.Gene Ther. 17(1) (2006) 117-124. 
[97] N. Tietze, J. Pelisek, A. Philipp, W. Roedl, T. Merdan, P. Tarcha, M. Ogris, E. 
Wagner, Induction of apoptosis in murine neuroblastoma by systemic delivery of 
transferrin-shielded siRNA polyplexes for downregulation of Ran. Oligonucleotides 
18(2) (2008) 161-174. 
[98] M.E. Davis, The first targeted delivery of siRNA in humans via a self-
assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol 
Pharmaceutics 6(3) (2009) 659-668. 
[99] J.D. Heidel, Z. Yu, J.Y. Liu, S.M. Rele, Y. Liang, R.K. Zeidan, D.J. Kornbrust, 
M.E. Davis, Administration in non-human primates of escalating intravenous doses of 
targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. 
Proc.Natl.Acad.Sci U.S.A 104(14) (2007) 5715-5721. 
[100] K. de Bruin, N. Ruthardt, K. von Gersdorff, R. Bausinger, E. Wagner, M. Ogris, 
C. Brauchle, Cellular dynamics of EGF receptor-targeted synthetic viruses. Mol Ther 
15(7) (2007) 1297-1305. 
[101] S. Kim, J. Jeong, S. Lee, S. Kim, T. Park, LHRH receptor-mediated delivery of 
siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-
LHRH conjugate and PEI. Bioconjug Chem 19(11) (2008) 2156-2162. 
[102] E. Wagner, C. Plank, K. Zatloukal, M. Cotten, M.L. Birnstiel, Influenza virus 
hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by 
transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer 
vehicle. Proc.Natl.Acad.Sci.U.S.A 89(17) (1992) 7934-7938. 
[103] J. Haensler, F.C. Szoka, Jr., Polyamidoamine cascade polymers mediate 
efficient transfection of cells in culture. Bioconjug Chem 4 (1993) 372-379. 
[104] C. Plank, W. Zauner, E. Wagner, Application of membrane-active peptides for 
drug and gene delivery across cellular membranes. Adv.Drug Deliv.Rev. 34(1) (1998) 
21-35. 
References                                                                                            
 
 
104 
[105] D.B. Rozema, K. Ekena, D.L. Lewis, A.G. Loomis, J.A. Wolff, Endosomolysis 
by Masking of a Membrane-Active Agent (EMMA) for Cytoplasmic Release of 
Macromolecules. Bioconjug.Chem. 14(1) (2003) 51-57. 
[106] S. Boeckle, J. Fahrmeir, W. Roedl, M. Ogris, E. Wagner, Melittin analogs with 
high lytic activity at endosomal pH enhance transfection with purified targeted PEI 
polyplexes. J.Control Release 112(2) (2006) 240-248. 
[107] E.J. Kwon, J.M. Bergen, S.H. Pun, Application of an HIV gp41-derived peptide 
for enhanced intracellular trafficking of synthetic gene and siRNA delivery vehicles. 
Bioconjug Chem 19(4) (2008) 920-927. 
[108] H. Mok, T.G. Park, Self-crosslinked and reducible fusogenic peptides for 
intracellular delivery of siRNA. Biopolymers 89(10) (2008) 881-888. 
[109] X.L. Wang, T. Nguyen, D. Gillespie, R. Jensen, Z.R. Lu, A multifunctional and 
reversibly polymerizable carrier for efficient siRNA delivery. Biomaterials 29(1) (2008) 
15-22. 
[110] E. Wagner, Strategies to improve DNA polyplexes for in vivo gene transfer: will 
"artificial viruses" be the answer? Pharm.Res. 21(1) (2004) 8-14. 
[111] E. Wagner, Programmed drug delivery: nanosystems for tumor targeting. 
Expert.Opin.Biol Ther 7(5) (2007) 587-593. 
[112] J.A. Wolff, D.B. Rozema, Breaking the Bonds: Non-viral Vectors Become 
Chemically Dynamic. Mol Ther 16(1) (2008) 8-15. 
[113] N. Murthy, J. Campbell, N. Fausto, A.S. Hoffman, P.S. Stayton, Bioinspired 
pH-Responsive Polymers for the Intracellular Delivery of Biomolecular Drugs. 
Bioconjug.Chem. 14(2) (2003) 412-419. 
[114] V.A. Sethuraman, K. Na, Y.H. Bae, pH-responsive sulfonamide/PEI system for 
tumor specific gene delivery: an in vitro study. Biomacromolecules. 7(1) (2006) 64-
70. 
[115] C. Fella, G.F. Walker, M. Ogris, E. Wagner, Amine-reactive pyridylhydrazone-
based PEG reagents for pH-reversible PEI polyplex shielding. Eur.J Pharm.Sci 34(4-
5) (2008) 309-320. 
[116] V. Knorr, M. Ogris, E. Wagner, An acid sensitive ketal-based polyethylene 
glycol-oligoethylenimine copolymer mediates improved transfection efficiency at 
reduced toxicity. Pharm.Res 25(12) (2008) 2937-2945. 
[117] M. Meyer, A. Philipp, R. Oskuee, C. Schmidt, E. Wagner, Breathing life into 
polycations: functionalization with pH-responsive endosomolytic peptides and 
polyethylene glycol enables siRNA delivery. J Am Chem Soc 130(11) (2008) 3272-
3273. 
[118] S. Matsumoto, R. Christie, N. Nishiyama, K. Miyata, A. Ishii, M. Oba, H. 
Koyama, Y. Yamasaki, K. Kataoka, Environment-responsive block copolymer 
micelles with a disulfide cross-linked core for enhanced siRNA delivery. 
Biomacromolecules 10(1) (2009) 119-127. 
[119] M. Meyer, C. Dohmen, A. Philipp, D. Kiener, G. Maiwald, C. Scheu, M. Ogris, 
E. Wagner, Synthesis and Biological Evaluation of a Bioresponsive and 
Endosomolytic siRNA-Polymer Conjugate. Mol Pharmaceutics 6(3) (2009) 752-762. 
[120] R.B. Merrifield, Solid Phase Peptide Synthesis. I.The Synthesis of a 
Tetrapeptide. J Am Chem Soc 85(14) (1963) 2149-2154. 
[121] L. Hartmann, E. Krause, M. Antonietti, H.G. Borner, Solid-phase supported 
polymer synthesis of sequence-defined, multifunctional poly(amidoamines). 
Biomacromolecules. 7(4) (2006) 1239-1244. 
References                                                                                            
 
 
105 
[122] L. Hartmann, S. Hafele, R. Peschka-Suss, M. Antonietti, H.G. Borner, Tailor-
made poly(amidoamine)s for controlled complexation and condensation of DNA. 
Chemistry 14(7) (2008) 2025-2033. 
[123] Q. Leng, P. Scaria, J. Zhu, N. Ambulos, P. Campbell, A.J. Mixson, Highly 
branched HK peptides are effective carriers of siRNA. J Gene Med 7(7) (2005) 977-
986. 
[124] Q. Leng, A.J. Mixson, Small interfering RNA targeting Raf-1 inhibits tumor 
growth in vitro and in vivo. Cancer Gene Ther. 12(8) (2005) 682-690. 
[125] V. Russ, H. Elfberg, C. Thoma, J. Kloeckner, M. Ogris, E. Wagner, Novel 
degradable oligoethylenimine acrylate ester-based pseudodendrimers for in vitro and 
in vivo gene transfer. Gene Ther 15(1) (2008) 18-29. 
[126] D. Schaffert, N. Badgujar, E. Wagner, Novel Fmoc-polyamino acids for solid-
phase synthesis of defined polyamidoamines. Org Lett 13(7) (2011) 1586-1589. 
[127] D. Schaffert, C. Troiber, E.E. Salcher, T. Frohlich, I. Martin, N. Badgujar, C. 
Dohmen, D. Edinger, R. Klager, G. Maiwald, K. Farkasova, S. Seeber, K. Jahn-
Hofmann, P. Hadwiger, E. Wagner, Solid-Phase Synthesis of Sequence-Defined T-, 
i-, and U-Shape Polymers for pDNA and siRNA Delivery. Angew Chem Int Ed Engl 
50(38) (2011) 8986-8989. 
[128] V. Russ, T. Frohlich, Y. Li, A. Halama, M. Ogris, E. Wagner, Improved in vivo 
gene transfer into tumor tissue by stabilization of pseudodendritic oligoethylenimine-
based polyplexes. J Gene Med 12(2) (2010) 180-193. 
[129] C. Scholz, E. Wagner, Therapeutic plasmid DNA versus siRNA delivery: 
Common and different tasks for synthetic carriers. J Control Release in press (2012). 
[130] B. Panaretou, G. Siligardi, P. Meyer, A. Maloney, J.K. Sullivan, S. Singh, S.H. 
Millson, P.A. Clarke, S. Naaby-Hansen, R. Stein, R. Cramer, M. Mollapour, P. 
Workman, P.W. Piper, L.H. Pearl, C. Prodromou, Activation of the ATPase activity of 
hsp90 by the stress-regulated cochaperone aha1. Mol Cell 10(6) (2002) 1307-1318. 
[131] L. Hartmann, E. Krause, M. Antonietti, H.G. Borner, Solid-phase supported 
polymer synthesis of sequence-defined, multifunctional poly(amidoamines). 
Biomacromolecules 7(4) (2006) 1239-1244. 
[132] M. Neu, J. Sitterberg, U. Bakowsky, T. Kissel, Stabilized nanocarriers for 
plasmids based upon cross-linked poly(ethylene imine). Biomacromolecules. 7(12) 
(2006) 3428-3438. 
[133] A. Beyerle, A. Braun, O. Merkel, F. Koch, T. Kissel, T. Stoeger, Comparative 
in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in 
mice. J Control Release 151(1) (2011) 51-56. 
[134] M. Kursa, G.F. Walker, V. Roessler, M. Ogris, W. Roedl, R. Kircheis, E. 
Wagner, Novel Shielded Transferrin-Polyethylene Glycol-Polyethylenimine/DNA 
Complexes for Systemic Tumor-Targeted Gene Transfer. Bioconjug.Chem. 14(1) 
(2003) 222-231. 
[135] E. Dauty, J.S. Remy, T. Blessing, J.P. Behr, Dimerizable cationic detergents 
with a low cmc condense plasmid DNA into nanometric particles and transfect cells in 
culture 106. J.Am.Chem.Soc. 123(38) (2001) 9227-9234. 
[136] C. Dohmen, T. Frohlich, U. Lachelt, I. Rohl, H.P. Vornlocher, P. Hadwiger, E. 
Wagner, Defined Folate-PEG-siRNA Conjugates for Receptor-specific Gene 
Silencing. Mol Ther - Nucleic Acids 1 e7 (2012). 
[137] J.J. Turek, C.P. Leamon, P.S. Low, Endocytosis of folate-protein conjugates: 
ultrastructural localization in KB cells. J Cell Sci 106 ( Pt 1) (1993) 423-430. 
[138] J.F. Kukowska-Latallo, K.A. Candido, Z. Cao, S.S. Nigavekar, I.J. Majoros, 
T.P. Thomas, L.P. Balogh, M.K. Khan, J.R. Baker, Jr., Nanoparticle targeting of 
References                                                                                            
 
 
106 
anticancer drug improves therapeutic response in animal model of human epithelial 
cancer. Cancer Res 65(12) (2005) 5317-5324. 
[139] C. Plank, B. Oberhauser, K. Mechtler, C. Koch, E. Wagner, The influence of 
endosome-disruptive peptides on gene transfer using synthetic virus-like gene 
transfer systems. J Biol Chem 269(17) (1994) 12918-12924. 
[140] E. Wagner, Functional Polymer Conjugates for Medicinal Nucleic Acid 
Delivery. Adv Polym Sci(247) (2012) 1-30. 
[141] T. Wang, J.R. Upponi, V.P. Torchilin, Design of multifunctional non-viral gene 
vectors to overcome physiological barriers: Dilemmas and strategies. Int J Pharm in 
press (2012). 
[142] Y. Sasaki, K. Akiyoshi, Nanogel engineering for new nanobiomaterials: from 
chaperoning engineering to biomedical applications. Chem Rec 10(6) (2010) 366-
376. 
[143] M. Molinos, V. Carvalho, D.M. Silva, F.M. Gama, Development of a Hybrid 
Dextrin Hydrogel Encapsulating Dextrin Nanogel As Protein Delivery System. 
Biomacromolecules in press (2012). 
[144] M. Nakanishi, R. Patil, Y. Ren, R. Shyam, P. Wong, H.Q. Mao, Enhanced 
stability and knockdown efficiency of poly(ethylene glycol)-b-
polyphosphoramidate/siRNA micellar nanoparticles by co-condensation with sodium 
triphosphate. Pharm Res 28(7) (2011) 1723-1732. 
[145] A.J. van Hell, D.J. Crommelin, W.E. Hennink, E. Mastrobattista, Stabilization 
of peptide vesicles by introducing inter-peptide disulfide bonds. Pharm Res 26(9) 
(2009) 2186-2193. 
[146] O. Taratula, O.B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V.P. 
Pozharov, H. He, T. Minko, Surface-engineered targeted PPI dendrimer for efficient 
intracellular and intratumoral siRNA delivery. J Control Release 140(3) (2009) 284-
293. 
[147] K.T. Love, K.P. Mahon, C.G. Levins, K.A. Whitehead, W. Querbes, J.R. 
Dorkin, J. Qin, W. Cantley, L.L. Qin, T. Racie, M. Frank-Kamenetsky, K.N. Yip, R. 
Alvarez, D.W. Sah, A. de Fougerolles, K. Fitzgerald, V. Koteliansky, A. Akinc, R. 
Langer, D.G. Anderson, Lipid-like materials for low-dose, in vivo gene silencing. Proc 
Natl Acad Sci U S A 107(5) 1864-1869. 
[148] J.P. Behr, The proton sponge: A trick to enter cells the viruses did not exploit. 
Chimia 51(1-2) (1997) 34-36. 
[149] C. Pfeifer, G. Hasenpusch, S. Uezguen, M.K. Aneja, D. Reinhardt, J. Kirch, M. 
Schneider, S. Claus, W. Friess, C. Rudolph, Dry powder aerosols of polyethylenimine 
(PEI)-based gene vectors mediate efficient gene delivery to the lung. J Control 
Release 154(1) (2011) 69-76. 
[150] H. Maruyama-Tabata, Y. Harada, T. Matsumura, E. Satoh, F. Cui, M. Iwai, M. 
Kita, S. Hibi, J. Imanishi, T. Sawada, O. Mazda, Effective suicide gene therapy in 
vivo by EBV-based plasmid vector coupled with polyamidoamine dendrimer. Gene 
Ther 7(1) (2000) 53-60. 
[151] J.H. Lee, Y.B. Lim, J.S. Choi, Y. Lee, T.I. Kim, H.J. Kim, J.K. Yoon, K. Kim, 
J.S. Park, Polyplexes assembled with internally quaternized PAMAM-OH dendrimer 
and plasmid DNA have a neutral surface and gene delivery potency. Bioconjug 
Chem 14(6) (2003) 1214-1221. 
[152] G. Navarro, G. Maiwald, R. Haase, A.L. Rogach, E. Wagner, C.T. de Ilarduya, 
M. Ogris, Low generation PAMAM dendrimer and CpG free plasmids allow targeted 
and extended transgene expression in tumors after systemic delivery. J Control 
Release 146(1) (2010) 99-105. 
References                                                                                            
 
 
107 
[153] M. Thomas, S.A. Kularatne, L. Qi, P. Kleindl, C.P. Leamon, M.J. Hansen, P.S. 
Low, Ligand-targeted delivery of small interfering RNAs to malignant cells and 
tissues. Ann N Y Acad Sci 1175 (2009) 32-39. 
[154] M. Oishi, Y. Nagasaki, K. Itaka, N. Nishiyama, K. Kataoka, Lactosylated 
poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage 
to construct pH-sensitive polyion complex micelles achieving enhanced gene 
silencing in hepatoma cells. J Am Chem Soc 127(6) (2005) 1624-1625. 
[155] S.H. Kim, J.H. Jeong, S.H. Lee, S.W. Kim, T.G. Park, PEG conjugated VEGF 
siRNA for anti-angiogenic gene therapy. J Control Release 116(2) (2006) 123-129. 
[156] S. Boeckle, J. Fahrmeir, W. Roedl, M. Ogris, E. Wagner, Melittin analogs with 
high lytic activity at endosomal pH enhance transfection with purified targeted PEI 
polyplexes. J Control Release 112(2) (2006) 240-248. 
[157] C. Plank, W. Zauner, E. Wagner, Application of membrane-active peptides for 
drug and gene delivery across cellular membranes. Adv Drug Deliv Rev 34(1) (1998) 
21-35. 
[158] M. Meyer, C. Dohmen, A. Philipp, D. Kiener, G. Maiwald, C. Scheu, M. Ogris, 
E. Wagner, Synthesis and Biological Evaluation of a Bioresponsive and 
Endosomolytic siRNA-Polymer Conjugate. Mol Pharm 6(3) (2009) 752-762. 
 
Acknowledgements                                                                                            
 
 
108 
8 Acknowledgements 
I am very thankful to all my colleagues for their support and the great time we spent 
together during the last years. Without you, work would not have been as prosperous 
and fun. 
First of all, I want to thank my supervisor Prof. Dr. Ernst Wagner for giving me the 
opportunity to join his research group and the trust and confidence he put in me. 
Thank you for your professional guidance and scientific support and for creating a 
working atmosphere of individual freedom and creativity, resulting in success for all 
members of the group. 
I am also very grateful to the other members of the “siRNA group”, David, Christian, 
Edith, Daniel, Irene, Uli, Petra, Claudia, Raphaela, Laura, Christina and Naresh for 
the great collaboration and discussions and for feeding me with a myriad of polymers 
during the Roche project. 
Kevin deserves a big thanks for the greatest work trip ever to L.A. and for all the 
great time we spent in the course of our studies. Thank you to all of the PhD room 
inhabitants/group for the countless “social events” in and out of the building. Rapid 
withdrawal from this group is not recommended due to the possible event of severe 
side effects. Special thanks to Daniel and Christian for the great support and 
collaboration and to my lab-mate Petra and Rebekka for having a great time in the 
laboratory and in cell culture. I want to thank Christian and Prajakta for guidance at 
the LSM and FACS and of course for the fun aside from work. 
A big thank goes to our technicians Miriam, Wolfgang, Anna, Markus, Ursula and 
Melinda for taking care of all the things that come up in order to keep the lab running. 
Many thanks to Alex Philipp for tutoring me at the beginning of my PhD thesis and for 
introducing me to cell culture. Also I would like to thank Dr. Martina Rüffer for her 
continuous guidance and patience with me during the various plant excursions, 
always seeming like a new world to me every year again. Many thanks also to the 
other group leaders, Andi and Manfred, and all other PhD students for the great time. 
Most of all I want to thank my family for their everlasting support, especially Bine and 
Markus for the countless sleepovers during this thesis and all the fun we had 
together with little Emma. 
